


# Frontiers in Cardiovascular Drug Discovery



**Editors:**  
**Atta-ur-Rahman, FRS**  
**M. Iqbal Choudhary**

**Bentham Books**

# **Frontiers in Cardiovascular Drug Discovery**

*(Volume 5)*

**Edited by**

**Atta-ur-Rahman, *FRS***

*Kings College,  
University of Cambridge,  
Cambridge,  
UK*

**&**

**M. Iqbal Choudhary**

*H.E.J. Research Institute of Chemistry,  
International Center for Chemical and Biological Sciences,  
University of Karachi, Karachi,  
Pakistan*

## **Frontiers in Cardiovascular Drug Discovery**

*Volume # 5*

Editor: Atta-ur-Rahman, *FRS* & Muhammad Iqbal Choudhary

ISSN (Online): 1879-6648

ISSN (Print): 2452-3267

ISBN (Online): 978-981-14-1324-7

ISBN (Print): 978-981-14-1323-0

© 2020, Bentham eBooks imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.net](mailto:permission@benthamscience.net).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

PREFACE .....	i
LIST OF CONTRIBUTORS .....	iii
<b>CHAPTER 1 THE LIPID HYPOTHESIS: FROM RESINS TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE-9 INHIBITORS .....</b>	<b>1</b>
<i>Sudarshan Ramachandran, Mithun Bhartia and Carola S. König</i>	
<b>INTRODUCTION .....</b>	<b>2</b>
<b>CHOLESTEROL .....</b>	<b>3</b>
Early Evolution of the Relationship between Cholesterol and Atherogenesis .....	3
<b>LONGITUDINAL PROSPECTIVE OBSERVATIONAL STUDIES AND CVD RISK ALGORITHMS .....</b>	<b>5</b>
<b>INTERVENTIONAL STUDIES WITH CLINICAL EVENTS AS OUTCOMES .....</b>	<b>10</b>
Randomised Controlled Bile Sequestrants Trials .....	12
Randomised Controlled Statin Trials .....	13
Randomised Controlled Ezetimibe Trials .....	19
Randomised Controlled PCSK9 Inhibitor Trials .....	20
<b>THE RECENT CASE AGAINST THE LIPID HYPOTHESIS .....</b>	<b>21</b>
<b>ROLE OF OTHER LIPID LOWERING AGENTS .....</b>	<b>21</b>
<b>ROLE OF ANTI-INFLAMMATORY THERAPY .....</b>	<b>22</b>
<b>REFINING THE LIPID HYPOTHESIS: IDENTIFICATION OF SUBGROUPS DEMONSTRATING EVEN GREATER BENEFIT .....</b>	<b>23</b>
<b>CONCLUSION .....</b>	<b>24</b>
<b>DISCLOSURE STATEMENT .....</b>	<b>24</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>24</b>
<b>CONFLICT OF INTEREST .....</b>	<b>24</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>25</b>
<b>REFERENCES .....</b>	<b>25</b>
<b>CHAPTER 2 THE ROLE OF SGLT2I IN THE PREVENTION AND TREATMENT OF HEART FAILURE .....</b>	<b>36</b>
<i>Hasan AlTurki, Ahmed AlTurki, Mark Sherman, Abhinav Sharma and Thao Huynh</i>	
<b>INTRODUCTION .....</b>	<b>36</b>
<b>HEART FAILURE .....</b>	<b>37</b>
<b>MECHANISMS OF ACTION OF SGLT2 AND SGLT2I .....</b>	<b>38</b>
Glucose Homeostasis .....	39
Cardiovascular Effects of SGLT2i .....	40
Nephroprotective Effects of SGLT2I .....	41
<b>CV OUTCOMES IN PATIENTS WITH T2DM .....</b>	<b>41</b>
<b>RENAL OUTCOMES IN PATIENTS WITH T2DM AND CHRONIC KIDNEY DISEASE (CKD) .....</b>	<b>45</b>
<b>HEART FAILURE .....</b>	<b>46</b>
<b>PERIPHERAL ARTERIAL DISEASE .....</b>	<b>47</b>
<b>ACUTE HEART FAILURE .....</b>	<b>48</b>
<b>REAL-WORLD DATA .....</b>	<b>49</b>
<b>CURRENT SGLT2I USES .....</b>	<b>49</b>
<b>CURRENT USE OF SGLT2 INHIBITORS IN CLINICAL PRACTICE .....</b>	<b>52</b>
<b>PRACTICAL CONSIDERATIONS WITH SGLT2I PRESCRIPTION .....</b>	<b>52</b>
<b>FUTURE DIRECTIONS AND ONGOING TRIALS .....</b>	<b>54</b>
<b>CONCLUSIONS .....</b>	<b>55</b>

CONSENT FOR PUBLICATION .....	55
CONFLICTS OF INTEREST .....	56
ACKNOWLEDGEMENTS .....	56
REFERENCES .....	56
<b>CHAPTER 3 NATURAL PRODUCTS AND SEMI-SYNTHETIC COMPOUNDS AS ANTITHROMBOTICS: A REVIEW OF THE LAST TEN YEARS (2009-2019)</b> .....	65
<i>Angelo Piato and Cedric Stephan Graebin</i>	
INTRODUCTION .....	65
NATURAL PRODUCTS WITH ANTITHROMBOTIC ACTIVITY .....	68
Antithrombotic Molecules Obtained from Marine-based Sources .....	68
<i>Antithrombotics from microorganisms</i> .....	73
Antithrombotics from Plant-based Sources .....	77
Semi-synthetic compounds with antithrombotic activity .....	92
CONCLUSION .....	97
ABBREVIATIONS .....	99
CONSENT FOR PUBLICATION .....	100
CONFLICT OF INTEREST .....	100
ACKNOWLEDGEMENT .....	100
REFERENCES .....	100
<b>CHAPTER 4 TRANSIENT RECEPTOR POTENTIAL CHANNELS: THERAPEUTIC TARGETS FOR CARDIOMETABOLIC DISEASES?</b> .....	108
<i>Leidyane Ferreira Gonçalves, Thereza Cristina Lonze Bargut and Caroline Fernandes- Santos</i>	
INTRODUCTION .....	108
TRP CHANNELS .....	109
TRPA (ankyrin) Family .....	110
TRPC (canonical) Family .....	111
TRPM (melastatin) Family .....	112
TRPML (mucolipin) Family .....	113
TRPP (polycystin) Family .....	114
TRPV (vanilloid) Family .....	114
TRP CHANNELS AND CARDIOVASCULAR DISEASES .....	116
TRP Expression .....	117
<i>TRPA1</i> .....	117
<i>TRPC</i> .....	117
<i>TRPM</i> .....	120
<i>TRPV</i> .....	122
Evidence of TRP Modulation in the Cardiovascular System .....	129
<i>TRPC</i> .....	129
<i>TRPV</i> .....	130
<i>Doxorubicin-induced Cardiotoxicity</i> .....	131
OBESITY AND DIABETES .....	132
TRP Expression .....	133
<i>TRPA1</i> .....	133
<i>TRPC</i> .....	134
<i>TRPM</i> .....	134
<i>TRPML and TRPP</i> .....	136
<i>TRPV</i> .....	136
Modulation of TRP Expression in the Adipose Tissue and Endocrine Pancreas .....	143
<i>TRPA1</i> .....	143

TRPC .....	144
TRPM .....	144
TRPV .....	145
<b>FUTURE PERSPECTIVES</b> .....	146
<b>CONCLUSION</b> .....	147
<b>CONSENT FOR PUBLICATION</b> .....	148
<b>CONFLICT OF INTEREST</b> .....	148
<b>ACKNOWLEDGEMENTS</b> .....	148
<b>REFERENCES</b> .....	148
<b>CHAPTER 5 TREATMENT OF RAYNAUD'S PHENOMENON</b> .....	164
<i>Sevdalina Nikolova Lambova</i>	
<b>PRIMARY RAYNAUD'S PHENOMENON</b> .....	166
Ginkgo Biloba .....	167
<i>Pharmacology</i> .....	167
<i>Clinical Trials</i> .....	167
<b>SECONDARY RAYNAUD'S PHENOMENON IN SYSTEMIC SCLEROSIS</b> .....	167
Calcium Channel Blockers .....	169
<i>Pharmacology</i> .....	169
<i>Clinical Data</i> .....	170
<i>Safety Profile</i> .....	171
Pentoxifyllin .....	171
<i>Pharmacology</i> .....	171
<i>Clinical Data</i> .....	172
<i>Safety Profile</i> .....	173
Nitric Oxide Pathway .....	173
<i>Phosphodiesterase-5 Enzyme Inhibitors</i> .....	173
<i>Topical Glyceryl Trinitrate</i> .....	175
Prostacyclin Pathway .....	176
<i>Iloprost</i> .....	177
<i>Epoprostenol</i> .....	179
<i>Prostaglandin E1 (Alprostadil)</i> .....	180
<i>Treprostinil</i> .....	180
<i>Oral Prostanoids</i> .....	181
Serotonin Inhibition – Fluoxetine .....	183
<i>Pharmacology</i> .....	183
<i>Clinical Data and Safety Profile</i> .....	184
Endothelin Pathway and Endothelin-Receptor Antagonists .....	184
<i>Endothelin Pathway</i> .....	184
<i>Clinical Data</i> .....	186
<i>Safety Profile</i> .....	187
Renin-Angiotensin System .....	188
<i>Angiotensin II Receptor Blocker – Losartan</i> .....	188
Angiotensin-Converting enzyme Inhibitors .....	189
Alpha-Adrenergic Blockers .....	190
<i>Prazosin</i> .....	190
<i>Alpha-2c Adrenergic Receptor Antagonists</i> .....	191
Statins .....	191
<i>Pharmacology</i> .....	191
<i>Clinical Data</i> .....	193
<i>Safety Profile</i> .....	193



Antiplatelet Therapy and Anticoagulants .....	193
Treatment of Digital Ulcers in Severe RP in SSc .....	195
Combination Therapy in Severe Peripheral Vascular Syndrome with Digital Ulcers in SSc .....	196
Other Treatments .....	197
<i>Botulinum Toxin</i> .....	197
<i>Rho-Kinase Inhibitors</i> .....	198
<b>CONCLUSION</b> .....	199
<b>CONFLICT OF INTEREST</b> .....	199
<b>ACKNOWLEDGEMENTS</b> .....	199
<b>REFERENCES</b> .....	199
<b>CHAPTER 6 TRADITIONAL MEDICINE BASED CARDIOVASCULAR THERAPEUTICS</b> .....	211
<i>Sriram Kumar, Rekha Ravindran, Sakthi Abbirami Gowthaman, Sujata Roy and Johanna Rajkumar</i>	
<b>INTRODUCTION</b> .....	212
Cardiovascular Diseases .....	212
Pathophysiology of CVD .....	212
Different Types of CVD .....	213
<b>INDIAN CARDIOVASCULAR THERAPEUTICS</b> .....	213
Ambrex .....	213
Abana .....	214
Arjunarishta .....	214
Arogh .....	215
BHUx .....	215
Lipistat .....	216
Liposem .....	216
Marutham .....	216
Triglize .....	217
<b>TRADITIONAL CHINESE MEDICINE</b> .....	217
Bushen Kangle .....	217
Dang Gui Long Hui Wan .....	217
Er Chen Wan .....	218
Fu Fang Dan Shen .....	218
Fu Fang Ge Qing .....	218
Jiang Zhi Ling .....	218
Jin Kui Shen Qi Wan .....	219
Ke Chuan .....	219
Qing Nao Jiang Ya .....	219
Sheng Mai Yin .....	219
Su He Xiang Wan .....	220
Tian Wang Bu Xin Dan .....	220
Tong Xin Luo .....	221
Xie Qing Wan .....	221
Xin Bao Wan .....	221
Yang Xin Yin .....	221
<b>INFORMATICS IN CVDD</b> .....	222
Herboinformatics in CVDD .....	222
Pharmacoinformatics in CVDD .....	222
Toxicoinformatics in CVDD .....	223
<b>CELLULAR MODELS FOR IN-VITRO RESEARCH</b> .....	225
Human Cardiac Myocytes .....	225

Human Aortic Endothelial Cells .....	225
Human Coronary Artery Endothelial Cells .....	226
Human Pulmonary Artery Endothelial Cells .....	226
Human Cardiac Microvascular Endothelial Cells .....	227
Human Pulmonary Microvascular Endothelial Cells .....	227
Human Dermal Microvascular Endothelial Cells .....	228
<b>CONCLUSION</b> .....	228
<b>CONFLICT OF INTEREST</b> .....	228
<b>ACKNOWLEDGEMENT</b> .....	228
<b>REFERENCES</b> .....	228
<b>CHAPTER 7</b> <b>CARDIOVASCULAR DISEASE: A SYSTEMS BIOLOGY APPROACH</b> .....	234
<i>Sujata Roy and Ashasmita S Mishra</i>	
<b>INTRODUCTION</b> .....	235
Cell-based Cardiac Disease Models and Animal Models .....	235
Post-genomic Era and Systems Biology Concept .....	236
<b>SYSTEMS BIOLOGY</b> .....	239
What is a Network and How to Construct? .....	239
From Network to Modules and Models .....	239
<b>SYSTEMS GENETICS</b> .....	241
Genomic Study and Genome-wide Association in Cardiovascular Traits .....	241
<b>SYSTEMS MEDICINE</b> .....	242
Integrative Biology .....	242
<b>DISEASE COMORBITIES AND NETWORK BIOLOGY</b> .....	243
<b>TOOLS AND DATABASES</b> .....	245
Public Data Sources, Prior Knowledge, and Data Integration .....	245
<b>CONCLUSION</b> .....	248
<b>CONSENT FOR PUBLICATION</b> .....	249
<b>CONFLICT OF INTEREST</b> .....	249
<b>ACKNOWLEDGEMENTS</b> .....	249
<b>REFERENCES</b> .....	249
<b>SUBJECT INDEX</b> .....	251

## PREFACE

According to the World Health Organization, cardiovascular diseases (CVDs) are globally the number one cause of death. Over 18 million lives are lost globally due to heart attack alone. CVDs range from benign arrhythmias to massive heart failures and from chronic hypertension to ischemic strokes. They occupy a central place in non-communicable diseases, and they are often the result of complex chronic metabolic disorders. Extensive researches have been conducted on the causes and treatments of CVDs. Changing lifestyle with high calories diets, sedentary life style, and smoking are among the key causes. Volume 5 of the book series **“Frontiers in Cardiovascular Drug Discovery”** covers 7 comprehensive reviews contributed by leading researchers. These reviews broadly cover various drug targets and new classes of therapies for the prevention or treatment of cardiovascular diseases.

The review by Ramachandran *et al* focusses on a fiercely debated topic in CVD, *i.e.* lipid hypothesis. Cholesterol and LDLs have since long been considered as risk factors of cardiovascular diseases. However, there is mounting evidence that challenge this dogma. The authors have carefully reviewed the scientific literature and conclude that the theory stands valid. Huynh *et al* present exciting new advancements of SGLT2i (Sodium-glucose cotransporters 2) inhibitors as an important new class of drugs. These inhibitors increase renal glucose excretion, and lead to natriuresis and glycosuria with subsequent reduction in blood glucose and associated CVDs in diabetic patients. Platelet aggregation and thrombosis are the major causes of morbidity and mortality worldwide. Piato and Graebin have reviewed recent literature on the development of antithrombotic agents of natural and semi-synthetic origins, with a higher level of safety. Santos *et al* have contributed a chapter on the significance of transient receptor potential (TRP) channels as potential drug targets against cardiometabolic diseases. Mutations in some of the TRP channels are implicated in various metabolic and cardiovascular disorders, and thus activations of TRP channels through natural products may lead to the development of a new class of drugs.

Raynaud’s phenomenon (RP), vasospasm due to cold exposure and emotional stress, is a common disorder. Lambova discuss various molecular approaches towards the treatment of RP. Traditional medicines have played an important role in the treatment of human diseases, including cardiovascular disorders. Ravindran *et al* have reviewed pharmacological, toxicological, and informatics studies, carried on various polyherbal formulations, in order to scientifically validate their efficacy against CVDs. The chapter by Roy and Mishra is focused on the applications of system biology approach in developing a better understanding of the molecular basis of the CVDs and its comorbidities. Special emphasis is paid to the identification of biomarkers for early diagnosis of CVD for a better management of the disease states.

*ii*

We would like to express our gratitude to all the authors of above cited review articles for their excellent contributions in this dynamic and exciting field of biomedical and pharmaceutical research. The efforts of the team of Bentham Science Publishers, particularly Ms. Mariam Mehdi (Assistant Manager Publications), and Mr. Mahmood Alam (Director Publications) are deeply appreciated.

**Atta-ur-Rahman *FRS***  
Kings College, University of Cambridge  
Cambridge  
UK

**&**

**M. Iqbal Choudhary**  
H.E.J. Research Institute of Chemistry  
International Center for Chemical and Biological Sciences  
University of Karachi  
Karachi  
Pakistan

## List of Contributors

<b>Ahmed AlTurki</b>	Division of Cardiology, McGill University Health Center, Montreal, Canada
<b>Abhinav Sharma</b>	Division of Cardiology, McGill University Health Center, Montreal, Canada
<b>Angelo Piato</b>	Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil
<b>Ashasmita S. Mishra</b>	Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India
<b>Cedric Stephan Graebin</b>	Departamento de Química Orgânica, Instituto de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, Brasil
<b>Carola S. König</b>	College of Engineering, Design & Physical Sciences, Brunel University London, London, United Kingdom
<b>Caroline Fernandes-Santos</b>	Instituto de Saude de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil
<b>Hasan AlTurki</b>	Department of Medicine, University of British Columbia,, Vancouver, Canada
<b>Johanna Rajkumar</b>	Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India
<b>Leidyanne Ferreira Gonçalves</b>	Instituto de Saude de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil
<b>Mark Sherman</b>	Division of Endocrinology, McGill University Health Center, Montreal, Canada
<b>Mithun Bhartia</b>	Apollo Hospitals, International Hospitals, Guwahati, Assam, India Dr Bhartia's Diabetes and Thyroid Clinic, Guwahati, Assam, India
<b>Rekha Ravindran</b>	Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India
<b>Sudarshan Ramachandran</b>	Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, West Midlands, United Kingdom Department of Clinical Biochemistry, University Hospitals of North Midlands/Faculty of Health Sciences, Staffordshire University/Institute of Science and Technology, Keele University/Staffordshire, United Kingdom College of Engineering, Design & Physical Sciences, Brunel University London, London, United Kingdom
<b>Sevdalina Nikolova Lambova</b>	Medical University - Plovdiv, Faculty of Medicine, Department of Propaedeutics of Internal Disease, Bulgaria
<b>Sriram Kumar</b>	Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India
<b>Sakthi Abbirami Gowthaman</b>	Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India

*iv*

<b>Sujata Roy</b>	Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India
<b>Thereza Cristina Lonzetti Bargut</b>	Instituto de Saude de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil
<b>Thao Huynh</b>	Division of Cardiology, McGill University Health Center, Montreal, Canada
<b>Thereza Cristina Lonzetti Bargut</b>	Instituto de Saude de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil
<b>Thao Huynh</b>	Division of Cardiology, McGill University Health Center, Montreal, Canada

## CHAPTER 1

# The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors

Sudarshan Ramachandran<sup>1,2,3</sup>, Mithun Bhartia<sup>4,5</sup> and Carola S. König<sup>3</sup>

<sup>1</sup> Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, West Midlands, United Kingdom

<sup>2</sup> Department of Clinical Biochemistry, University Hospitals of North Midlands / Faculty of Health Sciences, Staffordshire University / Institute of Science and Technology, Keele University / Staffordshire, United Kingdom

<sup>3</sup> College of Engineering, Design & Physical Sciences, Brunel University London, United Kingdom

<sup>4</sup> Apollo Hospitals, International Hospitals, Guwahati, Assam, India

<sup>5</sup> Dr Bhartia's Diabetes and Thyroid clinic, Guwahati, Assam, India

**Abstract:** The validity of the lipid hypothesis has been debated recently in both, the media and the medical press. In this chapter we review the relevant evidence to evaluate whether it is still applicable in cardiovascular prevention. After a brief description of developments leading to the lipid hypothesis we consider prospective epidemiological studies, paying particular attention to the Framingham Heart Study as it was conceived at a time when lipid lowering therapy was unavailable. We also present the predictive factors of the other commonly used cardiovascular risk scoring models. All the algorithms show cholesterol (total or low density lipoprotein – cholesterol) and high density lipoproteins to predict cardiovascular disease. Our own data from the Whickham Study where subjects were recruited in the pre-statin era also show total cholesterol to be significantly associated with coronary heart disease. We then discuss intervention randomised controlled studies using agents that lower low density lipoprotein – cholesterol (resins, statins, ezetimibe and Proprotein convertase subtilisin/kexin type 9 inhibitors) paying particular attention to studies not demonstrating reduction in cardiovascular outcomes. Apart from patients with heart failure and possibly on dialysis the lipid hypothesis appears to be true. This is reinforced by a meta-analysis carried out by the Cholesterol Treatment Trialists' Collaboration. We do not feel that outcomes from cohort studies consisting of patients subject to multiple guideline driven treatments can be used as good quality evidence against the lipid hypothesis. We do acknowledge that more research is required rega-

---

\* **Corresponding author Dr. S. Ramachandran:** Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation Trust, Good Hope Hospital, Rectory Road, Sutton Coldfield, West Midlands B75 7RR, United Kingdom; Tel: +44-121-424 7246; Fax: +44-121-311 1800; E-mail: sud.ramachandran@heartofengland.nhs.uk

Atta-ur-Rahman & M. Iqbal Choudhary (Eds.)  
All rights reserved-© 2020 Bentham Science Publishers

rding heterogeneity and describe a non-invasive way in which atherogenesis of the individual may be measured. We would like future randomised controlled trials to incorporate study of disease mechanism(s) within the study design.

**Keywords:** Cardiovascular disease, Cardiovascular disease prediction, Coronary heart disease, Ezetimibe, Framingham Heart Study, Lipid hypothesis, LDL-cholesterol, Peak systolic velocity, Proprotein convertase subtilisin/kexin type 9 inhibitors, Randomised Controlled Trials, Statins, Total cholesterol, Whickham study.

## INTRODUCTION

Atherosclerotic obstruction of arteries by plaque formation leading to cardiovascular disease (CVD) is one of the most common causes of mortality globally. Although the incidence has been decreasing [1], CVD still remains a leading cause of death in the United Kingdom [2]. Interestingly the prevalence of CVD has remained constant at about 3% [3] even though incidence has decreased, perhaps due to a fall in mortality. Thus, incidence and mortality rates and not prevalence may be the best indicators to evaluate CVD prevention measures. The Cholesterol Treatment Trialists' (CTT) Collaboration carried out meta-analyses of randomised controlled trials (RCTs) with a minimum of 1000 participants and concluded that a 1 mmol/l reduction in low density lipoprotein (LDL) - cholesterol was associated with a reduction in myocardial infarction, revascularisation and ischaemic stroke by just over 20% [4]. The lipid hypothesis describes this widely observed association between CVD risk and raised serum total cholesterol and LDL- cholesterol. Thus, a recent editorial in the *New England Journal of Medicine* describing the results of the IMPROVE-IT study, convincingly supported the hypothesis on the basis of prospective longitudinal studies showing significant decreases in CVD following use of LDL-cholesterol reducing agents, such as statins and ezetimibe [5].


However, there are publications arguing against the causative effect of cholesterol and LDL-cholesterol in the pathogenesis of atheroma and these have raised doubts regarding the benefit of lipid lowering therapy and indeed, the validity of the lipid hypothesis [6, 7]. This view contrasts with data showing statistically significant reductions in CVD using drugs that reduce LDL-cholesterol by different mechanisms. We speculate that the prevalent guideline culture in clinical medicine requires complex diseases to be simplified to aid the use of treatment pathways. Heterogeneity of populations, based on the degree of risk and mechanisms leading to risk, is often not considered [8]. After describing the history of the development of the lipid hypothesis we will consider epidemiology and interventional trials and how they fit in with the lipid hypothesis. In this



chapter it is not our intention to list details of the various trials, but to discuss and place the lipid hypothesis in the context of CVD prevention.

## CHOLESTEROL

Cholesterol is found in body tissues and plasma of animals and is a ubiquitous constituent of cell membranes. It is a precursor of bile acids, vitamin D and steroid hormones such as cortisol, aldosterone, testosterone, oestrogens and progesterone. Further, it is important in the development / functioning of the nervous system, and is involved in signal transduction and sperm development. The structure of cholesterol is shown in Fig. (1) and the molecule can exist in either free or esterified (a fatty acid covalently attached to the hydroxyl group at position 3 of the ring) forms.



**Fig. (1).** Structure of cholesterol with the point of esterification highlighted.

### Early Evolution of the Relationship between Cholesterol and Atherogenesis

We now consider major historical landmarks in the evolution of the lipid hypothesis, including the advent of evidence-based medicine *via* clinical trials. Controversy regarding the lipid hypothesis has ranged ever since Nikolai Anitschkow in 1913 demonstrated that rabbits when fed with purified cholesterol dissolved in sunflower oil developed vascular lesions similar to atheroma, this not being the case when the animals were fed just sunflower oil [9]. Anitschkow's findings were not confirmed in rats or dogs, hence the observation was considered to be specific to the rabbit model and cast aside. The fact that dietary cholesterol in rats and dogs did not translate into elevated serum cholesterol, perhaps due to high conversion of cholesterol to bile acids as suggested by Anitschkow, was not

## The Role of SGLT2i in the Prevention and Treatment of Heart Failure

Hasan AITurki<sup>1</sup>, Ahmed AITurki<sup>2</sup>, Mark Sherman<sup>3</sup>, Abhinav Sharma<sup>2</sup> and Thao Huynh<sup>2,\*</sup>

<sup>1</sup> Department of Medicine, University of British Columbia, Vancouver, Canada

<sup>2</sup> Division of Cardiology, McGill University Health Center, Montreal, Canada

<sup>3</sup> Division of Endocrinology, McGill University Health Center, Montreal, Canada

**Abstract:** Diabetes mellitus (DM) is an important independent risk factor for incident heart failure (HF). DM is also a prominent prognostic factor for major cardiovascular (CV) adverse events in patients with established HF with reduced (HFrEF) or preserved ejection fraction (HFpEF). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are recently approved drugs for DM treatment. SGLT2i lead to natriuresis and glycosuria with subsequent reductions in blood glucose, intravascular volume, and blood pressure. SGLT2i demonstrated a remarkable relative risk reduction in hospitalization for heart failure in large CV outcome trials of patients with DM. In addition, there was a more modest but also a relevant reduction in CV mortality with empagliflozin. SGLT2i reduce recurrent myocardial infarctions in patients with prior myocardial infarction. SGLT2i were subsequently evaluated in patients with HFrEF, including those without DM. Dapagliflozin was associated with reductions in the primary composite endpoint of worsening heart failure or CV death and each component separately. Considering their remarkable CV benefits and nephroprotection, SGLT2i represent invaluable therapy for the primary and secondary prevention of heart diseases in patients with DM or HFrEF. Ongoing trials may confirm the potential impact of SGLT2i in patients with HFpEF and acutely decompensating HF.

**Keywords:** Diabetes Mellitus, Heart Failure, SGLT2 Inhibitors.

### INTRODUCTION

Diabetes Mellitus (DM) is a common disease associated with debilitating microvascular and macrovascular consequences [1, 2]. Macrovascular diseases can lead to acute coronary syndromes, heart failure (HF), and cardiovascular (CV) death, which is the most common cause of death in this population [3 - 5].

\* Corresponding author **Thao Huynh:** Division of Cardiology, McGill University Health Center, Montreal, Canada; Tel: 514-934-1934 Ext-44649 ; Fax: 514-934-8569; E-mail: thao.huynhthanh@mail.mcgill.ca

The mainstay of DM management is optimal glycemic control [1, 2].

In 2008, the American Food and Drug Administration (FDA) mandated a compulsory assessment of long-term CV outcomes in all trials evaluating novel anti-diabetic agents [6]. Similar requirements were also set forth by the European Medicines Agency [7]. Both recommendations were in response to a meta-analysis by Nissen and colleagues, which showed 43% and 64% increased odds of myocardial infarction and CV death, respectively, associated with rosiglitazone [8]. Subsequently, rosiglitazone was banned or severely restricted globally. In the later ten years following the above recommendation, 22 randomized controlled trials (RCTS) were completed or ongoing to assess CV outcomes in anti-diabetic agents [9]. Almost all novel anti-diabetic agents were non-inferior to placebo for CV safety [10 - 14] except for one notable exception with increased risk of heart failure (HF) hospitalizations (HHF) associated with saxagliptin [15]. Glucagon-like peptide 1 agonists show excellent glycemic control and weight loss [12]. In 2016, the LEADER trial showed a reduction in the major adverse cardiovascular outcome (MACE), including CV death with liraglutide [16]. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) emerged with promising CV benefits in several safety trials [17 - 19]. In this chapter, we will review the impact of SGLT2i in the primary and secondary prevention of CV diseases with an emphasis on HF.

## **HEART FAILURE**

HF is a complex clinical condition characterized by the heart's inability to provide adequate forward flow or filling without pulmonary congestion [20 - 22]. HF has been declared a global pandemic affecting over 26 million people worldwide [23]. HF is classified into two main categories. HF with preserved left ventricle's ejection fraction and HF with reduced left ventricle's ejection fraction [21]. The importance of HF resides in two essential facts. First, HF is common with an annual incidence of 1% and a lifetime risk of 20% [24, 25]. Second, HF is generally associated with poor outcomes [26]. The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study reported six-month mortality and repeated HHF approximating 5% and 23%, respectively [27].

The Canadian Enhanced Feedback for Effective Cardiac Treatment (EFFECT) study demonstrated 30-day and 1-year heart failure readmissions of 4.9% and 16.1%, as well as mortality of 7.1% and 25.5%, respectively, in 1,570 patients with HFrEF [28]. During the last two decades, angiotensin pathway inhibitors, beta-blockers, and mineralocorticoid receptor antagonists (so-called triple therapies) have markedly improved heart failure outcomes [29]. However, despite

the triple therapies, the residual risks of HF-related hospitalization and mortality remain high and innovative approaches are needed.

Patients with DM have more than twice the risk of developing HF than individuals without DM [30]. DM-induced cardiomyopathy has been postulated as HF in the absence of coronary artery disease and hypertension in patients with DM [31]. The potential causal factors of DM cardiomyopathy include oxidative stress, inflammation, apoptosis, and microvascular coronary artery disease. In the Framingham Heart Study, DM independently increased the risk of HF up to two-fold in men and five-fold in women compared with age-matched controls (adjusted for age, hypertension, dyslipidemia, and coronary artery disease) [32, 33]. The prevalence of DM in HF patients is three to four-fold higher than the general population [34]. Moreover, DM is independently associated with increased risks of death and HFrEF in individuals with HF [35, 36]. HF was responsible for a substantial mortality burden of patients with DM in the TECOS trial [37].

Since elevated HbA1c level is associated with an increased incidence of HF [38], one may postulate that intensive glycemic control would reduce CV, and specifically HF-related outcomes. Unexpectedly, trials designed to evaluate the above hypothesis showed the contrary. The ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation) demonstrated that intensive glucose control, aiming for HbA1c 6.5% or better, failed to reduce macrovascular events or total mortality [39]. The ACCORD trial (Action to Control CV Risk in Diabetes), showed that intensive glycemic control (HbA1c of 6% and less) increased mortality by 22% compared to patients in the standard treatment arm [40]. Castagno *et al* completed a meta-analysis of eight RCTs evaluating the reduction in HF by an intensive glucose-lowering regimen compared to standard treatment in 37,229 patients [41]. The mean difference in the HbA1C level between the standard treatment and an intensive regimen was 0.9% (follow-up ranging from two to ten years) [41]. Overall, the risk of HF-related events was similar between the intensive and standard treatment arms (odds ratio (OR)1.20; 95% confidence interval (CI): 0.96-1.48) [41].

## **MECHANISMS OF ACTION OF SGLT2 AND SGLT2I**

In this section, we will examine the potential mechanisms by which SGLT2i may be beneficial in the prevention and treatment of HF. We summarize the mechanisms by which SGLT2i exert its cardioprotective effects in Fig. (1).

## Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019)

Angelo Piato<sup>1,\*</sup> and Cedric Stephan Graebin<sup>2,\*</sup>

<sup>1</sup> Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil

<sup>2</sup> Departamento de Química Orgânica, Instituto de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, Brasil

**Abstract:** Pathologies associated with hypercoagulable states, including myocardial infarction, deep vein thrombosis, and pulmonary embolism, are one of the most important causes of morbidity and mortality worldwide. Despite the approval of several new synthetic (including orally active) antithrombotic agents in recent years for treating such diseases, mainly direct thrombin, and factor Xa inhibitors, concerns still exist for side-effects, especially bleeding. There is still a therapeutic demand for safe and effective anticoagulant agents that present fewer side effects than the currently available drugs. Natural products and semi-synthetic molecules, as well as molecules inspired by natural scaffolds, have been an important source of drugs in the past decades. This chapter covers reports published in the last ten years concerning natural (or semi-synthetic) products that have been reported as *in vitro* and/or *in vivo* antithrombotic agents.

**Keywords:** Antithrombotics, Anticoagulants, Antiplatelets, Drug Discovery, Fibrinogen, Factor Xa, Medicinal Chemistry, Natural Products, Platelet Aggregation, Semi-Synthesis, Thrombin.

### INTRODUCTION


Cardiovascular diseases (CVDs) (or circulatory diseases) is a collective term for a group of diseases and disorders of the heart and blood vessels, such as coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism [1].

\* Address correspondence to Angelo Piato: Departamento de Farmacologia, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil; Tel: +55 (51) 3308-3121; E-mail: angelopiato@ufrgs.br, Cedric S. Graebin: Departamento de Química Orgânica, Instituto de Química, Universidade Federal Rural do Rio de Janeiro, Seropédica, Brasil; Tel: +55 (21) 2682-1872; E-mail: cedric@ufrj.br

According to data from the World Health Organization (WHO), CVDs are the major cause of death globally, both in developed and developing countries. In 2016, an estimated number of 17.9 million people (31% of all global deaths) died from CVDs, being 85% of these deaths due to heart attacks and strokes. The annual mortality of CVDs is expected to reach approximately 23.6 million deaths by 2030 [1 - 4]. The WHO also estimates that at least 75% of the CVD-related deaths occur in low and middle-income countries, mostly due to the lack of preventive care and access to effective and equitable health care services [5, 6]. Also, the economic burden of CVDs in low and middle-income countries is significant; some studies affirm that CVDs and the burden they bring to patients can be a cause of poverty itself [7]. In the past few years, the number of CVD deaths in high-income countries has declined but there is evidence pointing that this long-term decline is either staggering or reversing [8].

Natural products, with their chemical diversity and remarkable and complex structures, have been a significant source of therapeutic agents used to treat several diseases throughout the last centuries. Furthermore, semi-synthetic (*i.e.* compounds that were obtained from organic synthetic methods employing a natural product as starting material) and fully synthetic molecules whose pharmacophoric group is directly inspired from a natural source have also been an important source of new drugs [9 - 11]. Although it seemed that, in the past few years, natural products were being pushed aside in favor of fully synthetic drug candidates [12], it can be said that they are expendable experiencing a return of sorts as useful sources of hit and lead compounds [13-15]. In addition to that, the growing interest in natural products from marine sources [16] is revealing new and interesting bioactive molecules that are structurally diverse from ground-based natural products [17, 18].

Nonetheless, this “going out/in favor” trend regarding the use of natural products as drug candidates was not reflected in the scientific literature. Our search in the SCOPUS database<sup>†</sup>, looking for articles reporting the antithrombotic activity of natural products (search key: *TITLE-ABS-KEY (“natural products” OR alkaloid OR flavonoid OR terpene OR saponin OR polysaccharide) AND (antithrombotic OR antiplatelet OR anticoagulant OR thrombin OR “factor Xa” OR platelet)*) in the last 20 years has returned a steady growing trend (Fig. 1) which indicates that, despite the perceived lack of therapeutic applicability for natural products in the pharmaceutical industry in the past, the global community of researchers investigating the antithrombotic activity of natural products kept and continues to investigate these molecules and their biological properties.



**Fig. (1).** The plot of the number of published articles regarding the antithrombotic activity of natural products during 1999-2019. Search terms: (“natural products” OR alkaloid OR flavonoid OR terpene OR saponin OR polysaccharide) AND (antithrombotic OR antiplatelet OR anticoagulant OR thrombin OR “factor Xa” OR platelet) Source: SCOPUS.

Despite the recent approval of several new synthetic (including orally active) anticoagulant agents in recent years for treating such diseases, mainly direct thrombin, and factor Xa (fXa) inhibitors (Fig. 2), concerns still exist for side-effects, in particular the bleeding associated with their use [19 - 22]. Therefore, there is still a therapeutic demand for safe and effective antithrombotic agents that present fewer side effects than the currently available drugs.

In the past few years, several reports discussing the antithrombotic activity of natural (and semi-synthetic) products from several sources (plants, microorganisms, and marine organisms) have been published [23 - 27]. This chapter aims to cover these reports published in the last ten years concerning natural (or semi-synthetic) products that have been reported as *in vitro* and/or *in vivo* anticoagulants. Since one of the aims of this chapter is to highlight the molecular diversity of the natural products reported, we decided to focus our literature survey on isolated products. Reports concerning whole-extract activities without any indication of the active compound (or compounds) were, consequently, excluded. In order to have a more comprehensive discussion of the chemical entities reported, we decided to separate our findings into four categories: a) natural products from marine sources; b) natural products from

## Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases?

Leidyane Ferreira Gonçalves, Thereza Cristina Lonzetti Bargut and Caroline Fernandes-Santos\*

*Instituto de Saude de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil*

**Abstract:** Transient receptor potential (TRP) channels are ubiquitously expressed cellular sensors that respond to changes in the cellular environment. They act in nociception, taste perception, thermosensation, mechanosensing, osmolarity sensing, and signal transduction. Mammalian TRP channels comprise 28 members divided into six subfamilies: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin) and TRPV (vanilloid). TRP mutations that result in either gain or loss of function have been linked to several human diseases, among them hypertension, cardiac hypertrophy, obesity, and diabetes. In the myocardium, TRP channels modulate  $Ca^{+2}$  handling and are differentially expressed in models of cardiac remodeling and dysfunction. TRP channels are also involved in insulin release from pancreatic beta-cells and glucose tolerance in rodent models of type 2 diabetes. Some of these channels promote thermogenesis and thus prevent diet-induced obesity. How TRP channels are modulated *in vivo* is still unknown since few endogenous ligands were identified so far. However, a wide range of natural products with therapeutic potential activates TRP channels and might serve as models for new drug discovery and development to prevent cardiometabolic morbidity and mortality. Studies with TRP channels show promising results, but the translation to preventive or therapeutic strategies against cardiometabolic diseases is challenging since they are found in multiple tissues and enrolled in several physiological actions, which increases the risk of adverse effects.

**Keywords:** Adipose tissue, Cardiovascular diseases, Cardiometabolic syndrome, Heart, Obesity, Pancreas, Type 2 diabetes, Transient receptor potential channels, TRPA1, TRPC, TRPM, TRPV.

### INTRODUCTION

Cardiometabolic syndrome (CMS), also known as insulin resistance syndrome,

---

\* **Corresponding author Caroline Fernandes-Santos:** Instituto de Saude de Nova Friburgo, Universidade Federal Fluminense, Nova Friburgo, Rio de Janeiro, Brazil; Tel: +55 22 2528 7166; E-mail: cf\_santos@id.uff.br



syndrome X, Reaven's syndrome, and Beer belly syndrome, is recognized as a disease [1] and has been defined in several different ways [2]. However, the consensus is that it is a combination of metabolic disorders, such as insulin resistance, impaired glucose tolerance, systemic arterial hypertension, central obesity, and atherogenic dyslipidemia [1, 3]. Around 25% of the adult population worldwide is reportedly suffering from CMS [4].

CMS is commonly associated with the development of cardiovascular diseases, and as obesity increases worldwide, it has become a global pandemic [3]. The western way of life, characterized by a sedentary lifestyle and the increased consumption of high caloric unhealthy foods, has created a positive energy balance environment, increasing the risk for CMS and cardiometabolic diseases [3]. CMS is a significant public health concern owing to the financial impact of higher hospitalization rates due to comorbidities; it also impacts physical well-being and the quality of life and reduces the workforce. Therefore, it is crucial to develop therapeutic strategies focusing on both CMS risk factors and treatment of comorbidities [3].

Transient Receptor Potential (TRP) channels have been identified as potential candidates for the treatment of many diseases, including the cardiometabolic ones, as over the last 15 years supporting evidence has emerged on their role in cardiovascular and metabolic functions. TRP channels are a group of non-selective ion channel sensors that responds to a broad spectrum of physical and chemical stimuli, playing a role in the physiological process of signal transmission [5]. They are primary targets for both endogenous and exogenous substances with therapeutic potential [6]. However, translation to preventive or therapeutic strategies remains challenging as they are present in multiple tissues and thus, are enrolled in several physiological pathways, increasing the risk of adverse effects [6].

Here, we discuss whether TRP channels present an opportunity to combat cardiometabolic diseases, which are a high cost to governments and affect patient's well-being. Evidence shows that TRP channels are relevant as a therapeutic strategy, with additional research necessary to prove their safety and efficacy.

## TRP CHANNELS

Cosens and Manning described the first TRP channel in a *Drosophila melanogaster* mutant [7]. From then, until 2017, 28 mammalian TRP channel proteins have been identified. The TRP superfamily of channels is categorized into six families based on amino acid homologies: ankyrin (TRPA), canonical (TRPC), melastatin (TRPM), mucolipin (TRPML), polycystin (TRPP), and

vanilloid (TRPV) [5, 8]. The main structure of the TRP channel subunit has six transmembrane domains (TM1 to TM6) that are assembled as homo- or heterotetramers to form selective cation channels with diverse modes of activation and varied permeation properties [9]. They have distinct pharmacological properties, presenting a challenge in drug development [6, 10].

The TRPA family has only one protein identified (TRPA1). The TRPC family contains seven protein members (TRPC1-7), whereas the TRPM family includes eight members (TRPM1-8). The TRPML family contains three members (TRPML1-3), the TRPV family is comprised of six members (TRPV1-6), and the TRPP family has three proteins (TRPP1, TRPP2, and TRPP3) [5]. There is also a family called TRPN (NO-mechano-potential) found in worms, frogs, zebrafish, and *Drosophila*, with no homologous proteins in mammals [5]. TRP channels can be constitutively open or are activated by intracellular cations [5, 10]. While all TRP channels are permeable to cations, two TRP channels are impermeable to  $\text{Ca}^{2+}$  (TRPM4, TRPM5), and two others are highly  $\text{Ca}^{2+}$  permeable (TRPV5, TRPV6) [11].

TRP channels are found in the plasma membrane of distinct cell types, and cellular organelles such as lysosomes, endosomes and endoplasmic reticulum (ER), serving as intracellular ion channels [5]. They are activated in response to a variety of stimuli, including temperature, stretch, pressure, chemicals, oxidation/reduction, osmolarity, and pH, and interact with a range of proteins affecting their activity, location, and trafficking [5, 6]. They play a role in the physiological process of signal transmission [5], and are central elements of nociception, converting noxious stimuli into electrical pain signals [8]. Conversely, dysfunction of TRP channels is involved in various pathological conditions such as bladder disorders, cancer, obesity, type 2 diabetes (T2D), heart diseases, respiratory diseases and chronic pain [5]. The main TRP channels expressed in the cardiovascular system, pancreas, and adipose tissue (AT), which are the main focus of this chapter, are shown in Fig. (1).

### **TRPA (ankyrin) Family**

The TRPA1 channel is the only member of this family. This chemo-nociceptor is expressed in neurons, C-fibers, and myelinated  $\text{A}\beta$ -fibers, making it an ideal target for analgesics. It is also found in non-neuronal cells including epithelial cells, melanocytes, mast cells, fibroblasts, and enterochromaffin cells [12].

The TRPA1 channel is activated by various exogenous and endogenous compounds. The exogenous activator ligands are cysteine and lysine reactive electrophilic molecules like the active compound of mustard oil and wasabi (allyl isothiocyanate), cinnamaldehyde extracted from cinnamon, allicin from garlic

## Treatment of Raynaud's Phenomenon

Sevdalina Nikolova Lambova\*

*Medical University - Plovdiv, Faculty of Medicine, Department of Propaedeutics of Internal Diseases, Bulgaria*

**Abstract:** Raynaud's phenomenon (RP) represents a clinical expression of recurrent vasospasm of the small arteries and arterioles of the acral parts (most commonly fingers and toes) provoked by cold exposure and emotional stress. Here, the therapeutic strategies in primary and secondary RP in systemic sclerosis (SSc) are discussed that are based on the evolving knowledge about different pathogenic pathways of the peripheral vascular syndrome. The vasospasm in primary RP is reversible while the secondary SSc-related RP is associated with endothelial injury and subsequent structural abnormalities that lead to tissue damage. The disbalance between vasodilators (nitric oxide - NO, prostacycline) and vasoconstrictors (endothelin-1, angiotensin) is the major consequence of the endothelial injury in secondary SSc-related RP. Therapeutic options in primary RP patients include administration of oral, well-tolerated drugs such as herbal extracts from Ginkgo biloba, pentoxifyllin, or calcium channel blockers. European League Against Rheumatism recommends standardised therapeutic approach for management of SSc-related RP that includes administration of dihydropyridine-type calcium channel blockers, fluoxetine, phosphodiesterase type 5 inhibitors and intravenous iloprost. Other approaches have been also studied such as inhibition of renin-angiotensin system, statins, botulinum toxin but currently there is not enough evidence for their use. Scientific knowledge about mechanisms of action of different drugs corresponding to the underlying pathogenesis are discussed as well as available experience in RP regarding efficacy and safety profile. Individualization of therapy with using complex approach and drug combinations in resistant cases of severe RP and digital ulcers are presented.

**Keywords:** Angiotensin, Antiplatelet drugs, Aspirin, Bosentan, Endothelin, Digital ulcers, Fluoxetine, Iloprost, Nitric oxide, Nifedipine, Pathogenesis, Pentoxifyllin, Phosphodiesterase inhibitors, Prostacyclin, Raynaud's phenomenon, Serotonin, Sildenafil, Systemic sclerosis, Treatment.

Raynaud's phenomenon (RP) represents a clinical expression of recurrent vasospasm of the small arteries, arterioles and arteriovenous shunts of the acral

---

\* **Corresponding author Sevdalina Nikolova Lambova:** Medical University - Plovdiv, Faculty of Medicine, Department of Propaedeutics of Internal Diseases, Bulgaria

parts (most commonly fingers and toes) provoked by cold exposure and emotional stress [1]. It manifests usually in three phases with phasic skin colour changes *i.e.*, white discoloration in the phase of ischaemia, blue – in the subsequent phase of asphyxia and finally red discoloration - in the phase of reactive hyperemia. Skin colour changes are reversible and differ with distinct demarcation between the affected and unaffected area.

RP is classified into two subtypes - primary and secondary RP [1 - 4] that differ in pathogenic, clinical and prognostic aspects and require different therapeutic approaches. Primary RP is not associated with an underlying disease, differs with female predominance, family history, younger age at onset (below 30 years, mainly at puberty), but this phenomenon should be interpreted with caution as primary RP with late onset (above the age of 40) is also possible [5]. Prevalence of primary RP varying from 1.6 to 7.2% (calculated pooled prevalence 4.85%) was reported in a recent systematic literature review [6]. Clinically, primary RP is characterized with benign course, absence of digital ulcers, lack of symptoms and signs of underlying systemic autoimmune disease. Its diagnosis is generally based on the following criteria *i.e.*, **1)** vasospastic attacks precipitated by cold or emotional stress; **2)** symmetry of attacks; **3)** absence of digital ulcerations or gangrenes; **4)** normal erythrocyte sedimentation rate; **5)** negative test for antinuclear autoantibodies; **6)** normal capillaroscopic findings [7].

Contrary, secondary RP is a syndrome in the context of underlying disease. Secondary RP is a common clinical symptom in systemic autoimmune rheumatic disease and differs with highest prevalence of approximately 95% in systemic sclerosis (SSc)/scleroderma [2, 4, 8]. Secondary RP in rheumatic diseases is characterized by later age of onset above 30 years, presence of signs of connective tissue disease, more severe course with development of digital ulcers in a part of the cases, thumb involvement [2, 4, 9] (Fig. 1). Differential diagnosis of RP in rheumatic disease is broad and includes a spectrum of diseases that are characterized with varying prevalence of RP *i.e.*, SSc, mixed connective tissue disease, undifferentiated connective tissue disease, systemic lupus erythematosus, Sjögren syndrome, dermatomyositis, polymyositis, rheumatoid arthritis, systemic vasculitides (Buerger disease, Takayasu arteritis, polyarteritis nodosa, granulomatosis with polyangiitis, *etc.*), fibromyalgia, cryoglobulinaemia. RP could also be a sign of a spectrum of non-rheumatic pathology that also should be recognized and properly differentiated by the rheumatologists in routine clinical practice and includes cases of drug-induced RP by beta blockers, cytotoxic drugs – vinblastine, bleomycin, interferon, *etc.*; paraneoplastic RP – associated with solid tumours and haematological malignancies; vibration-induced white finger; hypothyroidism; carpal tunnel syndrome, *etc.* [2, 4, 8 - 15].



**Fig. (1).** Vasospastic attack in secondary SSc-related RP, phase of asphyxia with blue discoloration of the fingers; involvement of the thumbs is evident.

Different pathogenesis of primary and secondary RP results in different clinical course, severity, prognosis and respectively requires different therapeutic regimens. Here, the therapeutic strategies in primary and secondary RP in SSc are discussed. The vasospasm in primary RP is reversible while the secondary SSc-related RP is associated with endothelial injury and subsequent structural abnormalities that lead to tissue damage.

### **PRIMARY RAYNAUD'S PHENOMENON**

Non-pharmacological measures represent an integral part of the complex care for RP patients. Patients should be instructed to avoid cold exposure, to wear warm clothes and gloves, and to stop smoking. Moreover, in milder forms of primary RP, these measures may be enough to control the symptoms. In cases of specific exposures that are known to induce peripheral vasospasm, the contact should be restricted such as reduction of caffeine consumption, avoidance of known causative agents *i.e.*, beta blockers, interferons, use of protective devices by patients working with vibration [10].

## Traditional Medicine Based Cardiovascular Therapeutics

**Sriram Kumar, Rekha Ravindran\*, Sakthi Abbirami Gowthaman, Sujata Roy and Johanna Rajkumar**

*Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India*

**Abstract:** Cardiovascular diseases continue being the major cause of death worldwide, despite the constant and consistent efforts made towards the management and control of coronary artery diseases. These diseases are resulted by the metabolic imbalance involving elevated energy requirements and deficient oxygen supply to the cardiac myocytes, ultimately leading to myocardial necrosis. These diseases are closely associated with several changes in metabolic and signaling pathways that involve increased oxidative stress, excessive cytoplasmic and mitochondrial calcification, elevated lipid peroxidation, disturbed antioxidant homeostasis, dynamic cellular metabolism, irreversible DNA damage, and other pathophysiological alterations. The mechanism of pharmacological action demonstrated by modern western medicines usually adopt the lock-and-key model that involves the action of a principle therapeutic agent onto a specific and selective target to regulate a prime metabolic and signaling pathway, therefore becoming unsuitable to treat the disorders mediated by multiple molecular pathways. The side-effects associated with the use of such synthetic drugs are also an alarming health concern. The traditional system of medicine applies multiple natural ingredients that contain several active metabolites, therefore imparting a holistic pharmacological effect on multiple targets that orchestrate multiple pathways, without eliciting significant side-effects. This book chapter reviews various Indian and Chinese polyherbal formulations designed and developed according to the traditional system of medicine, which have been appropriately formulated and adequately characterized *in-vitro*, *in-vivo*, and *in-silico* following the stipulated scientific standards and medical regulations. Significant emphasis is also laid to review the informatic branches and cellular models available to evaluate and assess the pharmacology and toxicology of such polyherbal formulations.

**Keywords:** Ayurveda, Cardiovascular Diseases, Chinese Therapeutics, Cell Lines, Herboinformatics, Indian Therapeutics, *in-vitro*, Polyherbal Formulations, Pharmacoinformatics, Traditional Medicine, Toxicoinformatics.

\* **Corresponding Author Dr. Rekha Ravindran:** Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India; Email: rekha.ravindran@rajalakshmi.edu.in

## **INTRODUCTION**

### **Cardiovascular Diseases**

Cardiovascular disease is a general term for all types of diseases that affect the heart or blood vessels including numerous problems, many of which are related to a process called atherosclerosis. It is the major threat and cause of heart disease [1]. It is a condition that develops when a substance such as plaque builds up in the walls of the arteries. The build-up generally narrows the arteries making it harder for the blood to flow through. If a clot forms, it can also block the blood flow. Sometimes, this may even lead to a heart attack or stroke. CVD is generally associated with the build-up of fatty deposits inside the arteries and also associated with damage to arteries in an organ such as the brain, heart, kidneys, and eyes. Cardiovascular disease (CVD) is one of the leading causes of disability and death in the world. It is also regarded as the leading cause of mortality and morbidity in both men and women [2].

CVD is a class of diseases that involves heart and blood vessels. It also includes coronary artery diseases (CAD) such as myocardial infarction, commonly known as stroke and angina. Apart from this, other diseases that are associated with CVD are congenital heart disease, venous thrombosis, heart arrhythmia, rheumatic heart, heart failure, cardiomyopathy, stroke, hypertensive heart disease, valvular heart disease, and so on. Atherosclerosis is one of the main causes of CVD that includes the risk factor such as hypertension, hypercholesterolaemia and cigarette smoking, obesity, poor diet, and excessive alcohol consumption [3]. In the United States, 43% of the death rate is due to Cardiovascular disease [4]. In 1990, the death rate due to CVD was estimated to be 12.3 million (25.8%), while the death rate reached as high as 17.9 million (32.1%) in 2015 [5]. The death rate has been more in developing countries while the rate declined in most of the developed countries. Generally, older people are more affected by CVD.

### **Pathophysiology of CVD**

Studies show that atherosclerosis and diabetes are the major precursors for cardiovascular disease (CVD). Apart from this obesity, diabetes mellitus, hypercholesterolaemia, and chronic kidney disease are also often linked with cardiovascular disease [6]. Diabetes is the primary risk factor for CVD. It also affects the heart muscles leading to diastolic and systolic heart failure. Atherosclerosis is a major threat to people with macrovasculature even with or without diabetes [7].

## **Different Types of CVD**

There are many cardiovascular diseases involved in the heart and blood vessels. The type of CVD involved with the blood vessels (arteries, veins or capillaries) is known as vascular disease. They include diseases such as Aneurysm, Buerger's disease, Raynaud's disease or phenomenon, Atherosclerosis, Peripheral artery disease, Renal artery disease, Cerebrovascular disease (stroke), Peripheral venous disease, and other blood clotting disorders. The cardiovascular diseases associated with heart or cardiac are Arrhythmia (irregular heartbeat or rhythm), Angina (for both cardiac and vascular disease), Dilated cardiomyopathy, Heart attack, Congenital heart disease, Mitral valve prolapse, Mitral regurgitation, Pulmonary stenosis, Hypertrophic cardiomyopathy, and Rheumatic heart disease (a complication of strep throat) [6, 7].

## **INDIAN CARDIOVASCULAR THERAPEUTICS**

Following are some of the important Indian cardiovascular therapeutics that have attracted significant research interests:

### **Ambrex**

Ambrex is a licensed polyherbal formulation consisting of five Indian herbs: *Withania somnifera*, *Cycas circinalis*, *Orchis mascula*, *Shorea, robusta*, and amber (a resin from *Pinus succinifera*) that are "Generally safe" are blended together in accordance to the Siddha system of medicine. In a study, FTIR characterization of Ambrex demonstrated C=O stretching in carbonyl compounds contributed by the presence of high content of terpenoids and flavanoids [8], while the GC-MS analysis revealed Methyl-Commate-A as the key metabolite in its volatile-fraction [9]. An *in-vivo* study revealed that pre-treatment with Ambrex increases the ISPH-stimulated down-regulation of TCA-cycle enzymes (ICDH, SDH and  $\alpha$ -KGDH) and decreases the ISPH-induced up-regulation of apoptotic genes (p53, bax and caspase-3) and anti-apoptotic gene (bcl-2) to their normal levels [8]. Another study characterized the morphology of Ambrex formulation by SEM and assessed its cardioprotective activity against ISPH-induced myocardial necrosis in rats, by quantifying its effects on different oxidative stress markers and cardiac biomarkers through biochemical and histopathological evaluations. Ambrex serves as a unique metal-deficient to the best of our knowledge in siddha medicine based polyherbal nano-formulation characterized and evaluated in India. Pretreatment with Ambrex significantly maintained the tissue levels of oxidative stress markers and serum levels of cardiac biomarkers at their respective normals. It also attenuated the magnitude of ISPH-induced oxidative stress, ROS generation and LPO as reflected by biochemical evaluations, and ameliorated the degree of ISPH-induced myocardial necrosis and membrane damage as reflected



## Cardiovascular Disease: A Systems Biology Approach

Sujata Roy\* and Ashasmita S Mishra

*Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India*

**Abstract:** In the post-genomic era, the main challenge is to extract meaningful and valuable information from a large pool of data generated by high throughput techniques like microarray and deep sequencing techniques. Systems biology is an emerging discipline that aids in interpreting a large amount of biological data in a meaningful way. It helps to draw significant inference from a large amount of data about the interactions of genes or proteins, by developing quantitative mathematical models. Due to its complex nature, cardiovascular diseases can be better understood using the systems biology concept. Different components of the disease like heart failure and coronary artery disease can be comprehended in a modular fashion, wherein each module consists of multiple genes and their nonlinear interactions. Another approach is population genetics or Genome-Wide Association Studies (GWAS), which has identified over two hundred chromosomal loci that modulate the risk of cardiovascular diseases. These GWAS variation data can be integrated with multi-omics data and gene network data to identify the susceptible pathways, modules and genotyping cause behind it. Identification of a hub gene in a network is one of the main approaches of research in systems biology of cardiovascular diseases. This hub gene can serve as a biomarker for early detection or therapeutic targets. Comorbidities are another cause of increased risk leading to further complications in patients with cardiovascular diseases. Analysis of association of the comorbidities, using a system biology approach, focuses on the prevention of severe vascular events. The most common comorbidities include diabetes, kidney disease, peripheral arterial disease, *etc.* Systems biology can aid in identifying special biomarkers for early diagnosis of cardiovascular comorbidities and the following careful management might lead to prolonged survival of the patient.

**Keywords:** Bioinformatics, Cardiovascular Diseases, Data analysis, Disease comorbidities, Genome-wide association studies, Integrated omics, Network Biology, Network Medicine, Systems Biology.

\* **Corresponding author Sujata Roy:** Department of Biotechnology, Rajalakshmi Engineering College, Rajalakshmi Nagar, Thandalam, Chennai-602105, Tamil Nadu, India; E-mail: sujataroy@rajalakshmi.edu.in

## INTRODUCTION

Cardiovascular diseases (CVD) are the leading cause of death worldwide, mostly in low and middle-income countries. Despite the increasing economic and social burden of the disease, there is no proper understanding of its underlying mechanism. The Oslerian model is one of the old models in medical practice. According to this model, the presence of a given disease was identified by the anatomical abnormalities in organs and tissues. This practice has been evolved and improved over the last 100 years by methods of adopting a reductionist approach. This approach focuses on the individual analysis of the functional components of an organism. The cardiovascular disease is diversified in origin with a variety of biologically functional components. It can be defined by the presence of a cluster of cardiovascular risk factors, inflammatory changes to the vascular tissue, and development of the atherothrombotic process. The atherothrombotic process includes both atherosclerosis and its thrombotic complications. Atherosclerosis alone is a complex disease, caused by the combination of different facts like an aggregation of inflammatory cells and fibrous tissue in the wall of arteries.

### Cell-based Cardiac Disease Models and Animal Models

The aim of the reductionist approach was to define the individual basic units like the genes and pathways of the entire system by eliminating the complexity of it. But at the same time, simply focusing on the individual gene or pathway is not enough in comprehending the whole biological system in disease and health condition. The integration of multigene and multi pathways is the key process in understanding the system. In this context, cell culture-based systems and animal disease models play a major role to model the pathology observed in a patient. High-throughput technologies like microarray and next-gen sequencing technologies generate multifaceted data of these model systems. There is a need for analysis of integrated genomics, transcriptomics and proteomics for those model systems.

Different types of cells that contribute to the normal functioning of the heart are cardiac fibroblasts, endothelial cells, cardiomyocytes or vascular smooth muscle cells, among which the cardiac myocytes play a major role. Isolated primary neonatal cardiomyocytes from mice and rats are considered as excellent sources for differential gene expression studies. Reprogrammed embryonic stem cells (ESC) such as induced pluripotent stem cells (iPSCs) and engineered heart tissues (EHTs)/human cardiac organoids (hCOs) are used to generate cardiomyocytes [1 - 3]. Similarly, the use of zebrafish (*Danio rerio*) and large mammalian animal models has significantly contributed to the understanding of the disease

pathogenesis of cardiovascular disease in human beings. The high throughput data generated as outcomes from the high throughput experiments carried out in these model systems are the key resource of the data. Those data are analyzed using a series of bioinformatics tools or protocols which is called systems biology approach. This systems biology protocol leads to the development of diagnostic strategy and targeted therapies for human cardiovascular diseases.

**Table 1. Clinical understanding of chronic cardiac diseases with reductionism (Louridas *et al.*).**

<b>Medical Applications</b>	<b>Reductionism's Objectives</b>	<b>Systems Biology Holistic Strategy</b>
Clinical focus	Isolated clinical parameters	Interactions between components, like molecules, networks
Prevention	Isolated culprit molecular and environmental parameters	As an entity the whole range of culpable variables
Diagnosis	Isolated molecules, biomarkers, signs, symptoms	The patient as a "diseased person"
Therapy	Treating causes and symptoms	Treating the patient from a holistic perspective

### **Post-genomic Era and Systems Biology Concept**

Before the genomic era, a biological system was comprehended using a reductionist approach, an approach that believes in understanding complex things by dissecting them into simpler constituents. The molecular biology technique facilitates the studying of the composition, structure, and interactions of essential cellular molecules such as nucleic acids and proteins. Systems biology is not only just a combination of these molecular parts it may have something greater than that. A typical system-based study comprises the following five steps.

## SUBJECT INDEX

## A

- Acid 79, 90, 91, 92, 97, 111, 176, 177, 187  
 arachidonic 79, 90, 176, 177  
 citric 115  
 dihydrocaffeic 90  
 dihydroguaiaretic 92  
 glycyrrhetic 97  
 nitrooleic 111  
 propanoic 187  
 rosmarinic 97  
 shikimic 91  
 Acroischaemic syndromes 172  
 Actin cytoskeleton 198  
 Activation 80, 81, 110, 112, 116, 117, 129,  
 131, 177, 185, 192, 193  
 receptor-mediated 177  
 Activity 69, 74, 76, 85, 125, 144, 145, 177,  
 213, 214, 215, 216, 217  
 amidolytic 85  
 cardiac pacemaker 125  
 cardioprotective 213, 214, 215, 216  
 diuretic 217  
 fibrinolytic 74, 76, 177, 216  
 locomotor 144  
 metabolic 145  
 phospholipase 177  
 plasmin 74, 76  
 proteolytic 69  
 Adipogenesis 115, 134, 135, 137, 138, 139,  
 141, 145, 146  
 gene expression 139  
 inhibiting 146  
 Adipogenic differentiation 135, 139, 141  
 Adiponectin production 134, 139, 144  
 stimulate 144  
 ADP-induced platelet aggregation 77, 89  
 Aggregation 70, 171, 184, 193, 235  
 inhibited 70  
 Agonists 37, 112, 115, 135, 136, 144  
 endogenous 115  
 synthetic 136  
 Alzheimer's disease 6  
 American diabetes association (ADA) 50  
 Amino acid 109, 186  
 homologies 109  
 residues 186  
 Aminotransferases 187, 188  
 hepatic 187  
 Anaemia 175, 188  
 Angina 13, 19, 20, 48, 169, 173, 179, 212,  
 213, 215, 218, 221  
 cardiac 218  
 stable 169  
 unstable 19, 20, 48, 179  
 vasospastic 169  
 Angiogenesis 111, 225  
 impaired 225  
 Angiotensin-converting enzyme (ACE) 43,  
 52, 189, 194, 197  
 inhibitors 189  
 receptor blocker 43, 197  
 receptor neprilysin inhibitor (ARNI) 52  
 Antagonists 37, 96, 113, 115, 128, 137  
 endogenous 115  
 mineralocorticoid receptor 37  
 synthetic 113  
 Anticoagulant 65, 72, 77, 90, 92  
 agents, effective 65  
 properties 72, 77, 90, 92  
 Anti-diabetic agents 37, 53  
 evaluating novel 37  
 novel 37  
 Antithrombotic agents 65, 92, 97  
 effective 67  
 Anti-TNF-alpha antibody 226  
 Anxiety 174, 191  
 Apolipoprotein 241, 244, 245  
 Apoproteins 4, 5  
 Apoptosis 38, 122, 126, 128, 131, 132, 134,  
 138, 144, 226  
 doxorubicin-induced cardiomyocyte 131  
 increased cellular 226  
 mediated cardiomyocyte 132  
 myocardial 131  
 Apoptotic genes 142, 213  
 expression 142

Arterial hypertension 109, 169, 179, 190, 191, 227  
 pulmonary 179, 227  
 secondary 190  
 systemic 109  
 Assays 75, 77, 78, 82, 226  
 chromogenic substrate 82  
 luciferase 226  
 molecular docking 77  
 protease inhibition 75  
 silico docking 78  
 Atherosclerosis 4, 11, 15, 23, 212, 213, 215, 216, 217, 218, 225, 226, 228, 235  
 coronary 217  
 prevention and treatment of 216, 218  
 progression of 11, 15  
 risk factors 23  
 ATP 19, 114, 120, 171, 172  
 binding cassette (ABC) 19  
 in neonatal rat cardiomyocytes 120  
 increased erythrocyte 171  
 level depletion 171  
 Atrial natriuretic peptide (ANP) 117, 120, 122, 125, 128

## B

Balance 137, 145  
 negative energy 145  
 positive energy 137  
 Baseline 9, 11, 21, 23, 44  
 cholesterol 9, 11  
 CV disease 44  
 inflammation 23  
 LDL-cholesterol 21  
 measurements 9  
 Basilar artery 223  
 BAT activation 141, 145  
 Beer belly syndrome 109  
 Beta-adrenergic receptors property 214  
 Beta cell transplant 42  
 Beta-oxidation 53  
 hepatic 53  
 Beta-thromboglobulin 184  
 Bile acids 3, 12, 13  
 binding gut 12  
 sequestrants 12, 13  
 Bile salt export pump 186  
 Bis-substituted urea 96  
 Blood 4, 183, 212, 216, 217, 218, 219, 221

healthy 219  
 Blood cholesterol levels 4  
 Blood clotting 218  
 Blood coagulation 72  
 Blood flow 171, 172, 175, 177, 190, 198, 212  
 blood cell rigidity compromises 171  
 peripheral 172  
 reduction 190  
 renal 177  
 Blood glucose 36, 53, 142, 146  
 levels 53  
 Blood pressure 6, 8, 9, 12, 36, 41, 126, 130, 170, 172, 177, 214, 219, 220, 228  
 arterial 177  
 decreasing 41  
 diastolic 8  
 healthy 219  
 systolic 8, 12, 41  
 Body weight (BW) 6, 131  
 Botulinum toxin 164, 197, 198  
 Bradycardia 180, 221, 224  
 Brain natriuretic peptide (BNP) 43, 47, 117, 118, 120  
 Brown adipocytes 137, 140, 144  
 differentiation 137, 140  
 Brown adipose tissue (BAT) 113, 114, 132, 134, 136, 137, 138, 140, 141, 143, 145, 147  
 Buerger disease 165

## C

Caffeine consumption 166  
 Calcium channel blockers (CCBs) 164, 167, 169, 170, 174, 195, 197  
 Calcium channel-modulatory 215  
 Calcium levels 40, 177  
 cytosolic 177  
 increasing mitochondrial 40  
 Capsaicin 114, 115, 122, 128, 130, 131, 140, 141, 143, 145, 146, 147  
 activation member 114  
 Captopril prevention project (CAPP) 9  
 Cardiac 119, 224  
 adverse effects (CAE) 224  
 arrhythmias 119  
 Cardiac dysfunction 40, 128, 130, 131  
 doxorubicin-induced 128, 131  
 obesity-mediated 40  
 Cardiac events 17, 20

- composite major adverse 20
- developing major adverse 20
- Cardiac hypertrophy 108, 116, 117, 118, 119, 120, 122, 125, 129, 130, 131
  - development of 129, 130
  - diet-induced 128
  - pathological 116, 118
  - prevented TAC-induced 122
- Cardiac injury 40, 123, 126, 132, 147
  - doxorubicin-induced 126
  - morphogenesis 113
  - prevented doxorubicin-induced 132
- Cardiac myocytes 117, 119, 132, 211, 225, 235
  - rod-shaped freshly-isolated 225
- Cardiac remodeling 108, 116, 117, 131
  - adaptive 117
- Cardiogenesis 127
- Cardiometabolic 109
  - diseases, combat 109
- Cardiomyocyte hypertrophy 118, 120
  - attenuated 118
  - induced 118
  - mild hypoxia-induced 120
- Cardiomyocytes 116, 117, 119, 120, 122, 128, 129, 131, 235
  - cell-derived 120
  - primary neonatal 129
- Cardiomyopathy 42, 43, 120, 123, 127, 128, 212, 213
  - cardiac dystrophic 123
  - hypertrophic 120, 128, 213
  - obstructive 43
  - restrictive 42
- Cardio-renal protection 39
- Cardiotoxicity 123, 126, 127, 131, 132
  - attenuated doxorubicin-induced acute 123
  - doxorubicin-induced 123, 126, 127, 131, 132
- Cardiovascular disease 2, 214, 217, 219
  - prediction 2
  - treatment of 214, 217, 219
- Cerebrovascular disease 6, 65, 171, 173, 213
- Cervical 196, 197
  - dystonia 197
  - sympathectomy 196
- Chemerin adipokine 226
- Chemo-genomic enrichment analyses (CGEA) 244
- Chinese 80, 90, 211, 217, 218, 221, 228
  - herbal medicine 218, 221, 228
  - lacquer tree 80, 90
  - magnoliavine fruit 217
  - polyherbal formulations 211
- Cholesterol 1, 2, 3, 4, 6, 9, 12, 13, 16, 19, 22, 214, 215, 216, 241
  - dietary 3
  - elevated serum 3
  - low-density lipoprotein 241
  - structure of 3
- Cholesterol levels 4, 8, 13, 14, 192, 215, 216, 219
  - reducing 4
  - serum 4, 219
- Chronic 22, 41, 42, 45, 46, 50, 51, 116, 197, 212, 215, 217, 218, 236
  - cardiac diseases 236
  - cystitis 42
  - headaches 197
  - hemodynamic alterations 116
  - kidney disease (CKD) 22, 41, 45, 46, 50, 51, 212
  - myelogenous leukemia (CML) 217, 218
  - respiratory disease 215
- Cinnamaldehyde supplementation 143
- Clindamycin 196
- Coagulation 69, 72, 117
  - fibrinogen 69, 72
- Coagulation 68, 69, 98
  - cascade 68, 98
  - phenomena 69
- Collagen 69, 70, 72, 80, 84, 87, 90, 92, 93, 96, 97, 118, 130, 228
  - deposition 118
  - replacement 130
  - synthesis 228
- Combination therapy 196, 197
- Comorbidities 109, 132, 133, 138, 145, 234, 243, 244, 245
  - cardiovascular 234
  - random 243
- Competitive thrombin inhibitor 85
- Compound danshen formula (CDF) 243
- Computational flow dynamics 23
- Concentrations 40, 41, 172, 181
  - increased glucose 41
  - maximum plasma 181
  - plasma fibrinogen 172
  - plasma glucose 40
- Connective tissue 119, 165

- disease 165
  - growth factors (CTGF) 119
  - Consolidated standards of reporting trials (CONSORT) 11
  - Constipation 171, 191
  - Contractile function 116, 120, 122, 123, 128
  - Contractility 40, 125
    - resulting improved cardiac 40
  - Contraction 41, 198
    - decreased vascular smooth muscle cell 198
    - intravascular volume 41
  - Coronary artery diseases (CAD) 20, 38, 211, 212, 234, 240, 243
    - angiographic 20
    - microvascular 38
  - Coronary heart disease (CHD) 1, 2, 6, 7, 8, 9, 11, 12, 16, 18, 20, 23, 179, 215, 218
  - Cough 174, 190, 218, 219
    - dry 190
  - Counter cardiac arrhythmia 215
  - Crataegus pinnatifida* 77, 78
    - seeds 78
  - Creatinine 43, 44
  - CVD 2, 10, 18, 51
    - atherosclerotic 10, 51
    - significant reductions in 2, 18
  - CV death 36, 37, 42, 43, 44, 45, 46, 47, 48, 50, 51, 54, 55
    - and all-cause mortality 47
    - decreased 46
    - reduced 47, 48
    - reductions in 47
  - CV diseases 37, 41, 44, 45, 49, 51
    - atherosclerotic 45
    - pre-existing atherosclerotic 45
  - CVD 3, 5, 22, 66, 243
    - pathogenesis 22
    - prevention 3
    - related deaths 66
    - risk factors 5
    - treatment 243
  - CVD risk 7, 24
    - function scores 7
    - reduction 24
- D**
- Damage 184, 186, 211
    - hepatocellular 186
    - irreversible DNA 211
    - vascular 184
  - Data 235, 238, 242, 245, 246, 248
    - mass spectrometry 245
    - miRNA 245
    - multifaceted 235
    - proteomics 246, 248
    - transcriptomics 238, 242
  - Death 2, 16, 17, 19, 20, 23, 44, 46, 54, 235
    - cardiac 16
    - cardiovascular 16, 17, 19, 20, 23, 54
    - coronary 17
    - leading cause of 2, 235
    - renal 44, 46
  - Decreasing uricemia 41
  - Deficient oxygen supply 211
  - Deletion 119, 123, 124
    - single channel gene 119
  - Dense single-nucleotide polymorphism 241
  - Depletion, platelet serotonin 184
  - Depression 184, 191
  - Diabetes mellitus (DM) 18, 36, 38, 40, 41, 43, 48, 50, 51, 54, 55
  - Dialysis 1, 17, 18, 24
  - Diarrhoea 173, 174, 179, 180, 182, 183, 191
  - Dietary monoacylglycerols 145
  - Diet-induced obesity 108, 134, 136, 141, 143, 145
    - high-fat 136
  - Digital 165, 194, 195
    - gangrene 194, 195
    - ulcerations 165
  - Digital ulcers 164, 165, 167, 168, 169, 174, 176, 177, 180, 186, 187, 190, 194, 195, 196, 197, 198
    - active SSc-related 186
    - intractable 198
    - scleroderma-related 196
  - Disease 110, 113, 218, 234, 241, 242
    - causing genes 242
    - comorbidities 234
    - chronic 218
    - neurodegenerative 113
    - respiratory 110
    - susceptibility 241
  - Disorders 5, 65, 109, 110, 173, 211, 213, 214, 216, 218, 220, 224, 244, 247
    - bladder 110
    - blood clotting 213
    - cardiovascular 214
    - chronic kidney 244

- coronary artery 224
  - genetic 247
  - menstrual 218
  - metabolic 109, 216
  - myocardial 224
  - peripheral vascular 173
  - Dispelling rheumatism 217
  - Dizziness 171, 173, 182, 189, 191
  - DM 38
    - cardiomyopathy 38
    - induced cardiomyopathy 38
  - DNA 13, 238, 246
    - binding domains 13
    - methylation 238
    - sequence database 246
  - Downstream effector 198
  - Doxorubicin 131
    - induced cell atrophy 131
    - metabolites 131
  - Dysfunction 40, 45, 108, 110, 121, 126, 127, 128, 129, 131, 132, 174, 186, 221, 225
    - contractile 132
    - diastolic 131
    - erectile 129, 174
    - hepatic 186
    - human cardiac myocyte 225
    - left ventricular systolic 40
    - mitochondrial 121, 126
    - moderate renal 45
    - sinus node 221
  - Dysfunctional glucose metabolism 135, 139
  - Dyslipidaemia 14, 21, 23
    - atherogenic 21
  - Dyslipidemia 38, 109, 214
    - atherogenic 109
- E**
- Effects 41, 91, 130, 173, 177, 190, 192, 244
    - antagonistic 244
    - antiaggregatory 177
    - anticoagulant 91
    - cardiac 130
    - dermatological 173
    - hypotensive 190
    - natriuretic 41, 177
    - nephroprotective 41
    - pleiotropic 192
  - Electrical pain signals 110
  - Electrophoresis 4
  - Embllica officinalis* 216
  - Endocytosis 5
  - Endothelial 120, 164, 166, 168, 175, 199
    - independent manner 175
    - injury 164, 166, 168, 175, 199
    - nitric oxide synthase 120
    - human aortic 225
  - Endothelin 169, 184, 185, 186, 187, 188, 195, 197
    - pathway 184
    - receptor antagonist (ERAs) 169, 184, 185, 186, 187, 188, 195, 197
    - receptor antagonists 169, 184
  - End-stage renal disease (ESRD) 42, 43, 44, 45, 46
  - Engineered heart tissues (EHTs) 235
  - Enzymes 13, 99, 173, 183, 189
    - angiotensin-converting 189
    - phosphodiesterases 173
  - Epoprostenol therapy 180
  - ERAs, nonpeptide 185
  - Erythema 174, 179
  - Established CV disease 42
  - European association for the study of diabetes (EASD) 50, 51
  - Events 12, 13, 17, 22, 38, 44, 45, 54, 55, 114, 134, 234
    - hypoglycemic 44
    - macrovascular 38
    - major cardiovascular 17, 22, 45
    - recurrent hospitalization 54, 55
    - severe vascular 234
    - vesicular trafficking 114
  - Expression 115, 116, 117, 118, 119, 121, 122, 137, 138, 145, 146, 193, 226, 227, 239, 241, 242
    - module 241
    - of platelet activation markers 193
    - profiles 239
  - Extracts 68, 72, 77, 79, 80, 81, 82, 85, 90, 91, 97, 111, 164, 167
    - crude 97
    - herbal 164, 167
    - hydrophilic 77
  - Extra-terminal protein 227
- F**
- Factors 7, 36, 119, 120, 122, 128, 185
    - connective tissue growth 119



epigenetic 7  
 hypoxia-inducible 120, 128  
 profibrotic 185  
 prognostic 36  
 tumor necrosis 122  
 Fascaplysin 72  
 Fasting-induced hyperphagia 144  
 Fat oxidation 139, 141, 145  
 Fatty acids 3, 139, 144, 215  
   bound polyunsaturated 215  
   polyunsaturated 144  
 FDA-approved combinations 52  
 Fibroblasts 110, 116, 117, 119, 124, 184, 185,  
   194, 235  
   cardiac 124, 235  
   interstitial 184  
   sensitivity 194  
 Fibrosis 40, 117, 118, 119, 122, 123, 126, 127,  
   128, 130, 131, 184, 185, 194, 240  
   attenuated interstitial 117  
   cardiac 123, 240  
   myocardial 122, 126, 130  
   tissue 184, 185  
 Food and drug administration (FDA) 37, 47,  
   49, 53, 54, 179, 187, 221, 224, 225  
 Framingham heart study 1, 2, 6, 7, 8, 9, 22,  
   24, 38  
 Function 19, 23, 108, 109, 114, 121, 126, 133,  
   146, 215, 218, 219, 222, 238, 239, 240,  
   242, 243, 248  
   defective lysosomal 114  
   endothelial cell 23  
   healthy brain 219  
   mediating adipocyte 133  
   metabolic 109  
   stomach 218  
   tissue 146  
   vascular smooth muscle cell 240  
 Functional enzymatic domains 112

## G

Gastro-esophageal reflux disease 174  
 GC-MS analysis 213  
 Gene-encoded potassium ion 224  
 Gene expression 118, 134, 136, 139, 143, 245,  
   246  
   inflammatory 139, 143  
   lipolytic 139, 143  
   present reduced 134

patterns 245  
 Genes 116, 135, 136, 137, 139, 146, 226, 234,  
   235, 238, 239, 241, 242, 244, 245, 246,  
   248  
   adipogenic 136, 146  
   expressed 238  
   hypertrophic 116  
   tumour suppressor 226  
 Genetics 241  
 Genome 238, 241, 248  
   organelle 238  
 Genome-wide association studies (GWAS)  
   234, 241, 242  
 Ginkgo biloba 164, 167  
 GLP-1 and insulin secretion 143  
 Glucose 39, 40, 41, 134, 135, 139, 140, 142,  
   143, 144  
   fasting 139, 142  
   homeostasis 39, 41, 134, 135, 143, 144  
   intolerance 135, 140  
   metabolism 140, 144  
   reabsorption 41  
   transporter, low-affinity 39  
 Glycosides 77, 215  
   monoterpenoid 77  
 Gonadal white adipose tissue (GWAT) 240  
 Good manufacturing practice (GMP) 217  
 GRid-INdependent Descriptor (GRIND) 223  
 Guidelines, cardiovascular prevention 5  
 Gummi Olibanum 220

## H

Haematological malignancies 165  
 Haemodialysis 17, 18, 21  
 Haemostasis 177, 184  
 HDL-cholesterol 21, 22  
   and triglyceride values 21  
   raising agents 22  
 Heart 111, 112, 113, 116, 117, 118, 120, 121,  
   122, 123, 124, 125, 212, 213, 220, 224,  
   238  
   arrhythmia 212, 224  
   arteries 221  
   ischemic 238  
   rheumatic 212  
 Heart disease 1, 2, 6, 8, 12, 20, 36, 55, 65,  
   110, 179, 212, 213, 214, 215, 216, 217,  
   218, 221  
   congenital 65, 212, 213

- coronary 1, 2, 6, 20, 65, 179, 215, 218
  - hypertensive 212
  - ischemic 216, 217, 221
  - rheumatic 65, 213
  - severe coronary 179
  - structural 55
  - Heart failure 7, 43, 44, 51, 54, 55, 179, 212, 215, 217, 220, 221, 238
  - chronic 55, 179, 221, 238
  - congestive 7, 217, 220
  - hospitalization for 43, 44, 51, 54, 55
  - refractory chronic congestive 215
  - systolic 212
  - Heart weight (HW) 131
  - Hemostasis cascade 68
  - Heparin 72, 179, 194, 195
    - low molecular weight 194, 195
    - therapy 194
  - Hepatic injury 186, 187
  - High-fat diets display 134
  - High-throughput technologies 235, 238
  - Histopathological evaluations 213, 214
  - HMG-CoA reductase 13
    - genes encoding 13
  - Homeostasis 112, 114, 211, 214
    - disturbed antioxidant 211
    - intracellular antioxidant 214
    - lysosome ion 114
  - Homocysteine 16
  - Human 119, 121, 122, 225, 226, 228
    - aortic endothelial cells (HAEC) 225
    - atrial cardiomyocytes 122
    - atrial myocytes 121
    - coronary artery endothelial cells (HCAECs) 226
    - dermal microvascular endothelial cells (HDMECs) 228
    - pluripotent stem cell 119
  - Human cardiac 124, 128, 225, 227
    - fibroblasts 124
    - microvascular endothelial cells (HCMECs) 227
    - myocytes (HCM) 124, 128, 225
  - Human pulmonary 226, 227
    - artery endothelial cells (HPAECs) 226
    - microvascular endothelial cells (HPMECs) 227
  - Hyperglycemia 40, 142
  - Hyperhidrosis 197
  - Hypertension 7, 11, 38, 129, 212, 214, 215, 217, 219, 225, 238, 243
    - pulmonary artery 129
  - Hyperthermia 130
  - Hypertrophy 40, 116, 117, 118, 123, 124, 125, 128
  - Hypoglycemia 40, 43, 53
  - Hypotension 42, 171, 172, 176, 179, 191
    - and decreased vascular tone 172
    - pronounced 176
  - Hypothyroidism 165
  - Hypotonic cell swelling and heat 112
  - Hypoxia up-regulates chemerin expression 226
- ## I
- Immunofluorescent staining 225, 226, 227, 228
  - Infections 53, 54, 180, 196, 244
    - catheter-associated 180
    - fungal genital 54
  - Inflammation 22, 38, 41, 112, 115, 122, 123, 131, 132, 134, 137, 139, 141, 192, 195
    - monthly reducing 22
  - Inflammatory cytokines 225
  - Information 97, 222, 234, 244, 247, 248
    - genetic sequence 248
    - toxicological 222
  - Infusion 119, 177, 178, 179
    - single monthly 178
  - Inhibiting oxidative stress 131
  - Inhibition 40, 41, 69, 71, 72, 73, 74, 78, 79, 81, 86, 87, 93, 94, 95, 96, 123, 124, 125, 128, 129, 132, 133, 171, 172, 173
    - of platelet aggregation 78, 86, 87, 93, 94, 95, 96, 172
    - of platelet integrin 73
    - of proteolysis and protection 69
    - of thrombin activatable fibrinolysis inhibitor 74
    - of thrombin-induced fibrin polymerization 81
  - Inhibitors 77, 79, 164, 171, 197
    - non-selective phosphodiesterase 171
    - phosphodiesterase 164, 197
    - plasminogen-activated 79
    - serine protease 77
  - Insomnia 173, 174, 217, 220
    - treating 220

In-stent restenosis 130  
 Insulin 49, 53, 133, 138, 142, 145  
 Insulinemia 40  
 Insulin release 108, 138, 141, 142  
   glucose-stimulated 138  
 Insulin resistance 108, 109, 132, 134, 137,  
   138, 140, 141, 144  
   development of 132, 137  
   syndrome 108  
 Insulin secretion 40, 133, 135, 136, 138, 142,  
   143, 144, 145, 147  
   ameliorate 147  
   glucose-induced 135, 144  
   glucose-stimulated 142, 143  
   stimulated 133, 135  
 Intermediate density lipoproteins (IDL) 4  
 Intravenous iloprost 178, 179  
   infusions 178  
   therapy 179  
 Intravenous infusion 178, 180  
   prolonged 178  
 Intravenous prostanoid therapy 176  
 Ischaemia 165, 193, 197, 214  
   intractable 197  
   peripheral vascular 193  
 Ischaemic 16, 112, 172, 215, 223  
   lesions 172  
   cardiomyopathy 215  
   disease 16, 223  
   reperfusion injury 112, 215  
 ISPH-induced 213  
   myocardial necrosis 213  
   oxidative stress 213  
   up-regulation of apoptotic genes 213

**K**

Kidney disease 22, 41, 45, 51, 114, 212, 234  
   autosomal dominant polycystic 114  
   chronic 22, 41, 45, 51, 212  
   diabetic 50  
 Kyoto encyclopedia of genes and genomes  
   (KEGG) 246, 248

**L**

Lactate dehydrase 131  
 LDL-cholesterol 2, 5, 6, 8, 10, 11, 12, 14, 15,  
   16, 19, 20, 21, 24

and HDL-cholesterol values 8  
 decreased 12  
 efficacy 5  
 increased 6  
 reduction 11, 14, 20, 21, 24  
 reducing 14, 24  
 target 20  
 Left main coronary artery (LMCA) 120  
 Leptin levels 143  
 Lesions 3, 167, 187  
   necrotic 167  
   vascular 3  
 Leucocyte filterability 172  
 Leukocyte adhesion 225  
 Ligands 108, 112, 113  
   endogenous 108, 112  
   exogenous activator 110  
 Lipid 15, 21, 225, 244  
   homeostasis 244  
   lowering agents 21  
   lowering treatment 15  
   phosphate phosphatase 225  
 Lipophilic efficiency 223  
 Lipoprotein 4, 6  
   fractions 6  
   lipase 4  
 Liver 17, 177, 186, 187, 188, 193  
   cirrhosis 177  
   damage 187  
   enzymes 188  
   toxicity 186  
   transaminases 187, 193  
 Liver disease 42, 193, 218  
   chronic 218  
   nonalcoholic fatty 193  
 Logistic regression analysis 9  
 Low density lipoprotein (LDL) 1, 2, 4, 5, 10,  
   215, 216  
 Low-density lipoprotein receptor 240  
 LV 118, 123, 126  
   dysfunction 118, 126  
   hypertrophy 123  
 Lysosomal storage disease 114

**M**

Macrovascular diseases 36  
 Mechanisms 2, 5, 24, 38, 40, 55, 123, 130,  
   167, 170, 192, 194, 224  
   biochemical 224

calcineurin-dependent 130  
insulin-independent 40  
Medications 45, 48, 49, 50, 51, 53, 54, 190  
anti-diabetic 45, 49  
diuretic 53  
first-line anti-diabetic 51  
nephrotoxic 54  
second-line anti-diabetic 50  
Medicine 216, 211, 217, 228, 243  
ayurvedic 217  
herbal 216, 228  
therapeutic 217, 228  
traditional Indian 243  
traditional system of 211  
Melanocytes 110, 112  
Membrane 19, 40, 171, 172, 215  
basolateral 40  
bound phosphodiesterase 172  
jejunal brush border 19  
myocardial 215  
Metabolism 4, 146, 211, 238  
altered energy 238  
dynamic cellular 211  
lipoprotein 4  
Molecules 3, 65, 66, 69, 71, 72, 73, 98, 99,  
110, 114, 121, 132, 144, 147, 178, 185,  
224, 236  
adhesion 178  
anticoagulant 69, 73  
anti-inflammatory 132  
enhancing survival signaling 121  
natural non-caloric sweet-tasting 144, 147  
reactive electrophilic 110  
synthetic 66  
vascular cell adhesion 178  
Monthly pregnancy tests 187  
Morbidity 65, 108, 212  
cardiometabolic 108  
mRNA expression 117, 120, 223, 226  
increased 120  
levels 226  
Multiplex immunoassays 238  
Mutations 4, 114, 242, 248  
Myocardial 10, 43, 44, 45, 46, 48, 49, 117,  
120, 122, 126, 129, 130, 179, 223, 224,  
241  
development 122  
infarction (MI) 10, 43, 44, 45, 46, 48, 49,  
117, 120, 129, 130, 179, 223, 224, 241  
isoproterenol-induced 216

Myocardial 16, 211, 216, 217  
ischemia reduction 16  
necrosis 211, 216, 217  
Myocardium 108, 117, 121, 122, 215, 216  
adult ventricular 121  
hypoproliferation 121  
ischemia-reperfusion 117  
Myxobacterial strains 76

## N

Natural product androgapholide 96  
Natural products 66, 67, 77, 97, 98, 80, 98  
antithrombotic activity of 66, 67  
isolated 80  
marine-based 98  
microorganism-based 98  
plant-based 77, 97, 98  
Natural products and semi-synthetic  
molecules 65  
Natural scaffolds 65, 96, 97, 98  
Nausea 173, 179, 180, 182, 187, 191, 218  
Neonatal rat cardiomyocytes 120  
Neonate hearts 118  
Nervous system 3  
Network data exchange (NDEx) 246, 248  
Neuromuscular junction 197  
Nitroglycerin 176  
gel vehicle 176  
Nitroglycerin ointments 176, 197  
topical 197  
Nodularia spumigena 94, 96  
cyanobacteria 96  
NO-mediated pathway 197  
Non-coding regions elucidate 242  
Non-selective ion channel sensors 109  
Nucleic acids 236

## O

Obese 135, 136, 137  
diet-induced 137  
Obesity 139, 140  
counteracting 140  
and dysfunctional glucose metabolism 139  
Observation 3, 187  
post marketing 187  
Oedema 180, 188, 191  
peripheral 188

- pulmonary 180
- Oral 115, 243
  - bioavailability screening 243
  - cavity 115
- Organic synthetic methods 66
- Original cohort aging 6
- Orthostatic hypotension 179, 191
- Osmotic changes 115
- Osteomyelitis 195, 196
- Osteoporosis 6
- Overexpression 119, 120, 125
  - cardiac 119
- Oxidative stress 38, 40, 41, 117, 120, 122, 123, 126, 213, 215, 216
  - hypoxia-induced 117
  - markers 213
- P**
- PAF-induced platelet aggregation inhibition 88
- Pain 110, 174, 179, 180, 187, 188, 196, 198, 215, 217, 221
  - abdominal 187, 193
  - chest 174, 179, 180, 188, 215
  - chronic 110
  - jaw 180
  - leg 217
- Pancreas 39, 40, 42, 108, 110, 114, 116, 133, 136, 138, 143, 147, 218
  - adipose tissue and endocrine 116, 143, 147
  - inflamed 218
- Pancreatic  $\beta$ -cells 113, 133, 134, 135, 136, 138, 141, 144, 145
  - human 136
  - inflammation 144
  - isolated 135
- Pancreatitis 40
- Parathyroid hormone 115
- Parkinson's disease 6, 111
- Pathology 165, 175, 235, 238
  - non-rheumatic 165
  - well-recognized 175
- Pathophysiology 212, 227
  - of CVD 212
- Pathways 4, 14, 71, 72, 79, 90, 123, 173, 185, 188, 214, 234, 235, 244, 246
  - extrinsic coagulation 79, 90
  - intrinsic coagulation 98
  - intrinsic coagulation 71, 72, 90
  - lipid transport 4
  - signalling 214
  - susceptible 234
- Peptide 43, 47, 37, 51, 71, 72, 98, 117, 128, 130, 184
  - amino-acid 184
  - atrial natriuretic 117, 128
  - brain natriuretic 43, 47, 117
- Percutaneous coronary intervention 43
- Peripheral 47, 48, 54, 65, 213, 234, 243, 244
  - arterial disease (PAD) 47, 48, 54, 65, 234, 243, 244
  - venous disease 213
- Phenotypes 23, 130, 139, 140, 144, 240, 244
- atherogenic lipoprotein 23
  - lipolytic 139, 144
  - vascular smooth muscle 130
- Plasma insulin 142, 143
  - secretion 142
- Plasma protease 72
- Platelet aggregation 69, 72, 80, 81, 85, 86, 87, 90, 91, 92, 93, 94, 95, 96, 97, 98
  - collagen-induced 85, 91
  - factor (PAF) 87, 92
  - inhibited thrombin-induced 72
  - inhibiting thrombin-induced 97
- Platelet-leukocyte aggregates (PLA) 70, 72
- Platelet-rich plasma (PRP) 70
- Pluripotent stem cell (PSC) 118, 119, 129, 235
- Post-translational modification 192
- Pravastatin in ischemic disease 16
- Primary uncorrected valve disease 42
- Progesterone 3, 112
- Prognosis 4, 166
- Proinflammatory cytokines 136
- Proline-rich tyrosine kinase 121
- Prostacyclin 164, 176, 180, 182, 185
  - synthetic 180
- Prostacyclin receptor agonist 183
- Prostaglandins 111, 141
  - cyclopentenone 141
- Proteases 13, 197
- Protein kinase 129, 172
  - G (PKG) 129
- Protein-Protein Interaction 246
- Proteins 13, 19, 109, 110, 119, 120, 122, 234, 236, 239, 240, 241, 242, 246, 248
  - low-abundant intracellular 122
  - mammalian TRP channel 109
  - sterol response element binding 13

- Protein synthesis 130  
 Protein tyrosine kinase 129  
 Proteolysis 69  
 Prothrombin time (PT) 78, 79, 81, 83, 85, 90, 91  
 Pulmonary 37, 174, 179, 180, 183, 185, 187, 213, 223, 226, 227  
   arterial hypertension (PAH) 179, 180, 183, 185, 187, 227  
   congestion 37, 179  
   hypertension (PH) 174, 223, 226, 227  
   stenosis 213  
 Pulmonary thrombus 74, 76  
   degrading 76
- R**
- Reaven's syndrome 109  
 Receptors 72, 78, 111, 112, 119, 134, 135, 184, 185, 186, 187, 192  
   proliferators-activated 192  
 Regular hemodialysis 15  
 Regulating feeding behavior 135  
 Release 117, 132, 172, 183, 184, 194, 198, 225  
   cytokine 225  
 Renal 15, 16, 44, 177  
   failure, chronic 177  
   replacement therapy 44  
   transplantation 15  
   transplant recipients 16  
 Renal disease 21, 42, 43, 44, 45, 51  
   chronic 21  
   progression of 44, 51  
 Rhabdomyolysis 193  
 Rheumatic diseases 165, 199  
   systemic 199  
   systemic autoimmune 165  
 Rheumatoid arthritis 165  
 Rheumatologists 165, 169, 199  
 Rho-kinase Inhibitors 198  
 Risk factors 5, 6, 7, 9, 12, 23, 51, 212, 235, 244, 245  
   cardiovascular 235  
 Rosuvastatin therapy 18
- S**
- Salt 7, 90, 182  
   quaternary ammonium alkaloid 90  
 Saponin 66, 67, 91, 97  
   natural 97  
   triterpenic 91, 92  
 Saposhnikovia root 221  
 Sarcolemma 120, 126  
 Sarcomeric alpha-actinin 225  
 Sargassum micracanthum 93  
 Scavenging 167, 217  
   effects, radical 167  
   property, radical 217  
 Secondary 165, 167  
   raynaud's phenomenon 167  
   RP in rheumatic diseases 165  
 Secretion 39, 41, 53, 79, 81, 83, 132, 225, 241  
   glucagon 39  
   induced 79, 81, 83  
   uric acid 41  
 Semi-synthetic anticoagulant compounds 93  
 Serotonergic neurons 183  
   peripheral 183  
 Serotonin 164, 183, 184, 193, 194  
   inhibition 183  
   reuptake inhibitor 184  
   transporter 183  
 Serum creatinine 44, 45, 46  
 Severe peripheral vascular syndrome 196  
 Single-nucleotide polymorphism (SNP) 241  
 Skin keratinocytes 115  
 Sphingosine 113  
 Statins 20, 192, 193, 198  
   high intensity 20  
   hydrophilic 192  
   lipophilic 192  
   pleiotropic effects of 192, 193, 198  
 Statin therapy 18, 19, 20, 192  
   high intensity 20  
   intensive 19  
 Sterol response element binding protein (SREBP) 13  
 Store-operated channels (SOCs) 111  
 Stroke 2, 7, 17, 20, 43, 44, 45, 46, 48, 49, 193, 212, 213, 218, 220  
   acute ischemic 218  
   cold 220  
   fatal 17  
   haemorrhagic 17, 193  
   ischaemic 2  
 Subcutaneous infusion 180  
 Surgery 13, 196

coronary bypass 13  
 Syndrome 16, 17, 19, 20, 23, 36, 43, 108, 147, 165, 197, 219, 220  
 acute coronary 16, 17, 19, 20, 36, 43  
 cardiometabolic 108, 147  
 carpal tunnel 165  
 kidney yang deficiency 219  
 metabolic 23  
 piriformis 197  
 post-concussion 220  
 Synthesis 96, 97, 172, 173, 184, 192, 194, 198  
 extracellular matrix 184  
 stimulate prostacyclin 172  
 thromboxane 172  
 Systemic 42, 164, 165, 167, 172  
 lupus erythematosus 165, 172  
 sclerosis 164, 165, 167  
 steroids 42  
 Systems biology 236, 247  
 holistic strategy 236  
 markup language (SBML) 247

## T

TCA-cycle enzymes 213  
 Teratogenicity 187  
 Testosterone deficiency 24  
 Therapeutic effect of Ginkgo biloba 167  
 Therapeutics 97, 213, 228  
 cardiovascular 213  
 nature-derived 228  
 Therapies 13, 21, 22, 23, 42, 48, 55, 146, 164, 179, 187, 193, 195, 236, 243, 245  
 adjunctive 193  
 anti-inflammatory 22, 23  
 disease-modifying 55  
 fibrate 21, 23  
 immunosuppressive 42  
 novel cardiovascular 245  
 Thermogenesis 108, 141  
 Thermogenic genes expression 140, 144  
 Thrombin activatable fibrinolysis inhibitor (TAFIa) 74, 77, 94, 97, 98  
 Thrombin-induced fibrinogen clotting 85  
 Thrombin 76, 77, 79, 81, 83, 95, 96, 99  
 induced fibrin polymerization 81  
 inhibitors 76, 77, 95, 96, 99  
 production 79, 83  
 Thrombolysis 43, 45  
 in myocardial infarction (TIMI) 43, 45

Thrombosis 77, 216, 225  
 Thrombotic complications 235  
 Tissue 114, 117, 185, 194, 215  
 biopsies 117  
 expression 114  
 fibroblasts 185  
 injury 215  
 ischaemia 194  
 Total cholesterol 1, 2, 6, 7, 8, 13  
 reducing 13  
*Toxicodendron vernicifluum* 80, 90  
 Traditional chinese medicine (TCM) 90, 218, 220, 243  
 Transcriptome 238, 241  
 profiling 241  
 Transcriptomics 224, 235, 245  
 Transforming growth 116, 184  
 Transient mobilization 193  
 Translocation 39, 191, 198  
 cold-induced 198  
 tissue glucose 39  
 Transport, high-affinity glucose 39  
 Transverse aortic constriction (TAC) 117, 118, 122, 123, 124, 125, 127, 128, 129, 130  
 Triglycerides 4, 7, 15, 21, 22, 215, 216  
 Tumorigenesis 112  
 Tumor suppressor 112

## U

Ulcers 182, 190, 195  
 active 182  
 chronic 195  
 infected 190  
 Umbilical cord veins 188  
 Underlying pathogenesis 164  
 Urinary 40, 43  
 excretion 40  
 glucose excretion 40  
 tract infection 43

## V

Vascular 38, 167, 169, 170, 179, 182, 194, 213, 226  
 complications 179, 182  
 disease 38, 213  
 endothelial growth factor expression 226

- injury 194
  - pathology 167
  - smooth muscles 169, 170
- Vasoconstriction 184, 185, 190, 191, 198
  - cold-induced 191
  - decreased 198
- Vasomotor reactions 174
- Vasospasm 130, 164, 166
  - coronary 130
- Vasospastic attacks 165, 167, 170, 172, 180, 181, 189
- Venous infusions 172
- Ventricular 127, 221
  - hypertrophy 127
  - remodelling 221
- Ventricular tachycardia 122, 127, 223
  - lethal 223
- Very low density lipoprotein (VLDL) 4
- Vomiting 173, 179, 180, 187, 218

## **W**

- Wall shear stress 23
- Weight gain 138, 143, 145, 146
  - high-fat induced 143
- Well-tolerated drugs 164, 167
- White adipocytes 132, 140, 141, 144
  - cultured 144
  - human 140, 144
- White atractylodes rhizome 220
- Wild type (WT) 118, 120, 128, 129, 143, 225
- World health organization (WHO) 66, 183

## **X**

- Xanthomatosis 4

## **Z**

- Zebrafish caudal vessels 78





---

**PROF. DR. ATTA-UR-RAHMAN, FRS**

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.



---

**PROF. DR. M. IQBAL CHOUDHARY**

Dr. M. Iqbal Choudhary is a Professor of Organic/Bioorganic Chemistry and Director at the International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research). He is among the most prominent scientists of Pakistan, recognized for his original contributions in the fields of natural products and bioorganic chemistry. He has written and edited 27 books, most of which have been published in USA and Europe. He is also the author of over 900 research papers and chapters in top international science journals of the West as well as 27 US patents. He is the Volume Editor of many international book series and journals. He has served as a visiting faculty in many prestigious universities of the world including Cornell University (New York), Purdue University (Indiana), Pennsylvania State University (Pennsylvania), Scripps Institution of Oceanography (San Diego, California), The University of Rhode Island (Rhode Island), and other top Universities.